CN1017800B - Tricyclic compounds - Google Patents

Tricyclic compounds

Info

Publication number
CN1017800B
CN1017800B CN87106838A CN87106838A CN1017800B CN 1017800 B CN1017800 B CN 1017800B CN 87106838 A CN87106838 A CN 87106838A CN 87106838 A CN87106838 A CN 87106838A CN 1017800 B CN1017800 B CN 1017800B
Authority
CN
China
Prior art keywords
methyl
fluoro
oxo
dihydro
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CN87106838A
Other languages
Chinese (zh)
Other versions
CN87106838A (en
Inventor
青木雅弘
镰田美也子
大达男
新间信夫
横濑一辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN87106838A publication Critical patent/CN87106838A/en
Publication of CN1017800B publication Critical patent/CN1017800B/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention is concerned with tricyclic compounds of the general formula (I), as well as pharmaceutically acceptable salts thereof, and hydrates or solvates of the compounds of the formula I or their salts. Also included is a process for the manufacture of these compounds, pharmaceutical preparations containing them and intermediates useful in said process. The end products have antimicrobial antivity.

Description

Tricyclic compounds
The present invention relates to the tricyclic compound of a novelty, is pyrido (3,2,1-iJ)-1,3 specifically, 4-Ben Bing oxadiazine derivative, and their preparation method contains their pharmaceutical preparation and the useful intermediates in described method.
More particularly, the present invention relates to the pyrido (3 of the novelty of formula I representative, 2,1-iJ)-1,3, but the salt of 4-Ben Bing oxadiazine derivative and their hyoscine, and have the compound of formula (1) or the hydrate or the solvate of their salt, they all are the active principles in the antiseptic-germicide.
Figure 87106838_IMG10
（Ⅰ）
R wherein 1Be hydrogen atom or carboxylic acid-protecting group, R 2Be hydrogen atom or low alkyl group, the latter can be replaced by halogen; R 3And R 4Respectively be hydrogen atom or low alkyl group independently, the latter also can by hydroxyl or be substituted or unsubstituted amino replace; X is a halogen atom; R 5And R 6Respectively independently be hydrogen atom or can be by hydroxyl, lower alkoxy, the low alkyl group of the amino replacement of replacement or non-replacement; Perhaps, R 5And R 6Form 5 to 7 yuan of heterocycles with adjacent nitrogen together, this heterocycle can be replaced on carbon atom by one or more substituting groups, and heterocycle can contain-NR further 7-,-O-,-S-,-SO-,-SO 2-, or-NR 7-CO-(R 7Be hydrogen atom, low-grade alkenyl, low alkyl group or aralkyl, they also can be substituted, or the group of representing with the general formula II:
(wherein, n is from 0 to 4, R 8Be a hydrogen atom, a lower alkoxy, or amino, low alkyl group or aryl, they also can be substituted).
The corresponding group of above-mentioned defined formula I is described in detail as follows: term " rudimentary " is meant that carbochain preferably contains up to 7 and comprises 7 carbon atoms, except as otherwise noted.
R 1Explanation:
R 1Be hydrogen atom or carboxyl-protecting group.
In the above, carboxyl-protecting group is meant, as, low alkyl group such as methyl, ethyl, n-propyl, the tertiary butyl; Other meaning also has, and for example is easy to the carboxyl-protecting group of hydrolysis in vivo, such as rudimentary alkyloyloxyethyl alkyl (as acetyl-o-methyl, pivalyl oxygen methyl, 1-acetyl oxygen ethyl, and 1-pivalyl oxygen ethyl); Lower alkoxycarbonyl oxyalkyl (as the different third oxygen ketonic oxygen ethyl of methoxycarbonyl oxygen methyl, 1-ethoxycarbonyl-oxygen ethyl and 1-); Lactone group (as 2-benzo (C) furanonyl and sulfo-2-benzo (C) furanonyl); Rudimentary alkoxyl-methyl (as methoxyl methyl); Benzyloxymethyl; (5-methyl-2-oxo-1,3-dioxolane-4-yl) methyl; Or lower alkane amido methyl (as acetylamino methyl).Also available other ester group such as benzyl, cyanogen methyl, phenacyl, phenyl etc.
R 2Explanation:
R 2Be hydrogen atom or low alkyl group, the latter can be replaced by halogen atom.
In the above, low alkyl group preferably contains 1 to 4 carbon atom, particularly methyl, ethyl, n-propyl, sec.-propyl, normal-butyl etc., and halogen atom is a fluorine, and chlorine or bromine is preferably fluorine.
R 3And R 4Explanation:
R 3And R 4Can distinguish independent be hydrogen atom or low alkyl group, the latter can be replaced by amino hydroxyl or replacement or non-replacement.
In the above, low alkyl group preferably contains 1 to 4 carbon atom, particularly methyl, ethyl, n-propyl, sec.-propyl, normal-butyl etc.The amino that replaces can be two elementary alkyl amido such as dimethylamino, diethylin; Low-grade alkyl amino such as methylamino-, ethylamino; Rudimentary naphthene amino such as cyclopropylamino etc.
R 5And R 6Explanation:
R 5And R 6It independently is respectively the low alkyl group that a hydrogen atom or can be replaced by hydroxyl, lower alkoxy or one amino that replaced or non-replacement; Perhaps R 5And R 6Form 5 to 7 yuan of heterocycles with adjacent nitrogen-atoms, this heterocycle can be replaced on carbon atom by one or more substituting groups, and heterocycle can further contain-NR 7-,-O-,-S-,-SO-,-SO 2-or-NR 7-CO-(wherein, R 7Be hydrogen atom, low-grade alkenyl, low alkyl group or aralkyl, they also can be substituted; Perhaps for having a represented group of logical formula II,
(wherein, n is 0 to 4, R 8Be hydrogen atom, lower alkoxy, or amino, low alkyl group or aryl, they also can be substituted)).
Group defined above will be further explained in detail as follows:
Low alkyl group preferably contains 1 to 4 carbon atom, such as methyl, ethyl, n-propyl, sec.-propyl, normal-butyl etc.Lower alkoxy preferably contains 1 to 4 carbon atom, such as methoxyl group, oxyethyl group, positive propoxy, isopropoxy, n-butoxy etc.The amino that replaces can be two-low-grade alkyl amino, such as dimethylamino, diethylin, ethylmethylamino; Low-grade alkyl amino such as methylamino-, ethylamino, n-propylamine base, isopropylamino; Rudimentary naphthene amino such as cyclopropylamino etc.
By R 5And R 65 to 7 yuan of heterocycles that form can be piperazinyl, morphine quinoline base, thio-morpholine group, piperidyl, high piperazinyl, pyrrolidyl, pyrrolinyl, pyrryl, imidazolyl, triazolyl etc.Substituent example has hydroxyl, lower alkoxy such as methoxyl group, oxyethyl group, positive propoxy on the carbon atom on the heterocycle; Amino; Low-grade alkyl amino such as methylamino-, ethylamino, n-propylamine base, isopropylamino; Rudimentary naphthene amino is such as cyclopropylamino; Two-low-grade alkyl amino such as dimethylamino, diethylin, ethylmethylamino; The lower alkane amido is such as kharophen; Can be by the benzyl amino of nitro, amino, halogen, hydroxyl and/or lower alkoxy replacement, as (4-aminobenzyl) amino; One group of general formula is:
Wherein, R 50And R 51Be low alkyl group or together represent one 5 to 8 yuan saturated nitrogen heterocyclic, as (dimethylamino) methylene amino, (six hydrogen-1H-azepine with nitrogen-atoms
Figure 87106838_IMG12
-1-yl) methylene amino; Benzyloxy carbonyl amido; Halogen is such as fluorine, chlorine, bromine; Low alkyl group such as methyl, ethyl, n-propyl, sec.-propyl; Amino-low alkyl group, low-grade alkyl amino-low alkyl group, rudimentary naphthene amino-low alkyl group, two-lower alkyl amino-low alkyl group, lower alkane amido-low alkyl group, these substituent examples are: aminomethyl, (methylamino-) methyl, (ethylamino) methyl, (n-propylamine base) methyl, (isopropylamino) methyl, (cyclopropylamino) methyl, (dimethylamino) methyl, (diethylin) methyl, (ethylmethylamino) methyl, acetylamino methyl, the 2-amino-ethyl, the 2-(methylamino) ethyl, the 2-(ethylamino) ethyl, the 2-(diethylin) ethyl, the 2-(dimethylamino) ethyl, the 2-(ethylmethylamino) ethyl; Hydroxyl-(low alkyl group) such as methylol, 2-hydroxyethyl; Phenyl, it also can be replaced by amino, halogen, hydroxyl and/or lower alkoxy.Such as 4-aminophenyl, 4-fluorophenyl, 4-chloro-phenyl-, 4-hydroxyphenyl, 4-methoxyphenyl; A heterocycle is such as pyrryl, 4-methyl isophthalic acid-piperazinyl etc.
R 7The low-grade alkenyl of representative for example is an allyl group, 3-methyl-2-butene base, crotyl-1-methyl-2-propenyl, 3-butenyl etc.
By R 7The alkyl of replacement of representative is, for example, hydroxyl-(low alkyl group), such as the 2-hydroxyethyl, 3-hydroxyl butyl; Rudimentary alcoxyl-low alkyl group, such as the 2-methoxyethyl, the 2-ethoxyethyl; Amino-low alkyl group, such as the 2-amino-ethyl, the amino butyl of 3-; Low-grade alkyl amino-low alkyl group is such as the 2-(methylamino-) ethyl, the 2-(ethylamino) ethyl, the 3-(methylamino-) butyl, the 3-(ethylamino) butyl; Two-low-grade alkyl amino-low alkyl group, such as the 2-(dimethylamino) ethyl, the 2-(diethylin) ethyl, the 3-(dimethylamino) butyl, the 3-(diethylin) butyl; Halogen-low alkyl group is such as 2-fluoro ethyl, 3-fluoro-normal-butyl; Carboxyl-low alkyl group is such as carboxymethyl, 2-propyloic; Sulfo group-low alkyl group such as sulphur methyl, 2-sulfo group ethyl etc.
Can substituted aralkyl R 7For example be the benzyl and the benzyl that can be replaced by one or more following radicals, these groups have amino, nitro, low-grade alkyl amino, two-low-grade alkyl amino, halogen and/or lower alkoxy such as 4-aminobenzyl, the 4-nitrobenzyl, the 4-(dimethylamino) benzyl, 4-luorobenzyl, 4-benzyl chloride base, 3-methoxybenzyl, 4-methoxybenzyl, 3,4-veratryl etc.
Amino R 8Can be unsubstituted, or by as low alkyl group replacement, as methylamino-, dimethylamino, or replaced by low-grade cycloalkyl is as cyclopropylamino.
Low alkyl group R 8Can be similarly replacement or unsubstituted.By R 8The alkyl of replacement of representative is, for example, has carboxyl or lower alkoxycarbonyl, such as 2-propyloic, 3-carboxylic-n-propyl, 2-methoxycarbonyl ethyl, and 2-ethoxycarbonyl-ethyl, 3-methoxycarbonyl n-propyl or the like.
By R 8The aryl of representative is phenyl preferably; The aryl that replaces preferably has one or more halogens, lower alkoxy, hydroxyl, nitro and/or amino, such as 4-fluorophenyl, 4-chloro-phenyl-, 4-bromophenyl, 4-methoxyphenyl, 2-carboxyphenyl, 4-hydroxy phenyl, 4-nitrophenyl, 4-aminophenyl or the like.
By R 7What the group of representative was best is hydrogen; methyl; ethyl; n-propyl; sec.-propyl; the 2-hydroxyethyl; the 2-methoxyethyl; the 2-amino-ethyl; the amino normal-butyl of 3-; the 2-(methylamino-) ethyl; the 2-(ethylamino) ethyl; the 2-fluoro ethyl; carboxymethyl; the sulphur methyl; allyl group; the 4-aminobenzyl; the 4-luorobenzyl; formyl radical; ethanoyl; propionyl; benzoyl; the 4-amino benzoyl; 2-oxo-n-propyl; 2-oxo-normal-butyl; 3-oxo-normal-butyl; 3-oxo-n-pentyl; the 3-carboxypropanoyl; 3-ethoxy carbonyl propionyl; 4-carboxyl-positive butyryl radicals; benzyl formyl methyl, 4 '-the aminobenzoyl methyl; ethoxy carbonyl; methoxycarbonyl; formamyl or the like.
In formula I by R 5R 6The group that N-represents is preferably: the 1-piperazinyl; 4-methyl isophthalic acid-piperazinyl; 3-methyl isophthalic acid-piperazinyl; the 3-phenyl-peiperazinyl; 3; 4-dimethyl-1-piperazinyl; 4-ethyl-1-piperazinyl; the 3-(4-aminophenyl)-the 1-piperazinyl; 4-n-propyl-1-piperazinyl; the 4-(2-fluoro ethyl)-the 1-piperazinyl; 4-allyl group-1-piperazinyl; 4-(2-oxo-n-propyl)-the 1-piperazinyl; the 4-(carboxymethyl)-the 1-piperazinyl; 4-(3-oxo-normal-butyl)-the 1-piperazinyl; 4-(sulphur methyl)-the 1-piperazinyl; 4-(4-amino (benzyl)-1-piperazinyl; the 4-(2-hydroxyethyl)-the 1-piperazinyl; 3-oxo-1-piperazinyl; 4-phenacyl-1-piperazinyl; the 4-(3-carboxypropanoyl)-the 1-piperazinyl; 4-ethanoyl-1-piperazinyl; the 4-(4-nitrobenzyl)-the 1-piperazinyl; morpholino; 2-methyl-4-morpholinyl; 2; 6-dimethyl-4-morpholinyl; 4-thiol morpholinyl; 1-oxide compound-4-thiol morpholinyl; 1; 1-dioxide-4-thiol morpholinyl; the 4-(aminomethyl)-piperidino; the 4-[(methylamino-) methyl]-piperidino; 4-methoxyl group-piperidino; 4-hydroxyl-piperidino; the 4-(1-pyrryl)-piperidino; 4-amino-piperidino; the 1-(methylamino-)-piperidino; the 4-(ethylamino)-piperidino; the high piperazinyl of 1-; 4-methyl isophthalic acid-Gao piperazinyl; 3-amino-1-pyrrolidyl; the 3-(methylamino-)-the 1-pyrrolidyl; the 3-(ethylamino)-the 1-pyrrolidyl; 3-(benzyloxy carbonyl amido)-the 1-pyrrolidyl; the 3-(aminomethyl)-the 1-pyrrolidyl; 3-amino-4-phenyl-1-pyrrolidyl; 3-amino-3-methyl isophthalic acid-pyrrolidyl; 3-amino-4-methyl isophthalic acid-pyrrolidyl; the amino benzyl amino of 3-(4-)-the 1-pyrrolidyl; 3-(4-methyl isophthalic acid-piperazinyl)-the 1-pyrrolidyl; 3-((dimethylamino) methylene amino)-1-pyrrolidyl; 3-((methylamino-) methyl)-1-pyrrolidyl; 3-((methylamino-) methyl)-4-phenyl-1-pyrrolidyl; 3-methyl-3-((methylamino-) methyl)-1-pyrrolidyl; 3-((ethylamino) methyl)-1-pyrrolidyl; the 3-(acetylamino methyl)-the 1-pyrrolidyl; 3-((dimethylamino) methyl)-1-pyrrolidyl; 3-((ethylmethylamino) methyl)-1-pyrrolidyl; 3-amino-4-methoxyl group-1-pyrrolidyl; 3-methoxyl group-4-(methylamino-)-the 1-pyrrolidyl; the 3-(ethylamino)-4-methoxyl group-1-pyrrolidyl; 3-amino-4-chloro-1-pyrrolidyl; 3-chloro-4-(methylamino-)-the 1-pyrrolidyl; 3-chloro-4-(ethylamino)-4-fluoro-1-pyrrolidyl; 3-amino-4-fluoro-1-pyrrolidyl; 3-fluoro-4-(methylamino-)-the 1-pyrrolidyl; the 3-(ethylamino)-4-fluoro-1-pyrrolidyl; the 3-(aminomethyl)-4-chloro-1-pyrrolidyl; 3-chloro-4-[(methylamino-) methyl]-the 1-pyrrolidyl; 3-chloro-4-[(ethylamino) methyl]-the 1-pyrrolidyl; the 3-(aminomethyl)-4-fluoro-1-pyrrolidyl; 3-fluoro-4-[(methylamino-) methyl]-the 1-pyrrolidyl; the 3-[(ethylamino) methyl]-4-fluoro-1-pyrrolidyl; the 3-(aminomethyl)-4-methyl isophthalic acid-pyrrolidyl; 3-methyl-4-[(methylamino-) methyl]-the 1-pyrrolidyl; the 3-[(ethylamino) methyl]-4-methyl isophthalic acid-pyrrolidyl; 3-hydroxyl-1-pyrrolidyl; 3-methoxyl group-1-pyrrolidyl; 3-chloro-1-pyrrolidyl; 3-fluoro-1-pyrrolidyl; 3-hydroxyl-4-methoxyl group-1-pyrrolidyl; the 1-imidazolyl; 4-methyl isophthalic acid-imidazolyl; 3-amino-4-hydroxy-1-pyrrolidyl; the 3-(methylamino-)-4-hydroxyl-1-pyrrolidyl; the 3-(ethylamino)-4-hydroxyl-1-pyrrolidyl; the 3-(dimethylamino)-4-hydroxyl-1-pyrrolidyl; (2-(dimethylamino) ethyl) methylamino-, or the like.
The explanation of X:
X is a halogen atom, as fluorine, chlorine or bromine, preferably fluorine or chlorine.
The novel pyrido of formula I (3,2,1-iJ)-1,3, but the salt of 4-Ben Bing oxadiazine derivative and their hyoscine and their hydrate or the hydrate or the solvate of solvate and these salt can prepare by method of the present invention.It comprises:
(a) will lead to the compound of formula III representative and the amine reaction that general formula is (IV), subsequently, if desired, again protecting group be removed.
Figure 87106838_IMG13
（Ⅲ）
Wherein, R 1, R 2, R 3, R 4Identical with X with aforementioned definitions; X ' is a halogen atom, and the amino of existence, hydroxyl and/or carboxylic group can be protected.
Figure 87106838_IMG14
（Ⅳ）
Wherein, R 5And R 6As defined above, perhaps
(b) compound and the represented carbonyl compound of logical formula VI that general formula (V) is represented, perhaps its polymkeric substance, acetal, ketal or enol ether reaction then, if necessary, are removed protecting group again.
Figure 87106838_IMG15
（Ⅴ）
Wherein, R 1, R 2, R 5, R 6Identical with X with aforementioned definitions; The amino, hydroxyl and/or the carboxyl that exist can be protected,
Figure 87106838_IMG16
（Ⅵ）
Wherein, R 3And R 4Identical with aforementioned definitions, perhaps
(c) be preparation R 7Not the compound of the formula I of hydrogen, can be with R 7Be that the compound of formula I of hydrogen and one can generate R 70The reagent react of group, this radicals R 70With R 7With, but be not hydrogen, perhaps
(d) desire prepares the compound of formula I, wherein R 5And/or R 6Be low alkyl group (perhaps containing a two-low-grade alkyl amino or lower alkoxy), can will lead to the compound (R wherein of formula I 5Or/and R 6Be hydrogen or contain-amino low-grade alkyl amino or hydroxyl) carry out low alkyl groupization, perhaps
(e) for preparing the compound of formula I, wherein R 5R 6N-be have-SO-or-SO 2-5 to 7 yuan of heterocycles, then can with respective compound (wherein heterocycle contain-S-) carry out oxidation, perhaps
(f) for preparation contains free amine group, hydroxyl, and/or the formula I compound of carboxyl, the corresponding formula I compound that it can be had the amino, hydroxyl and/or the carboxyl that are protected is sloughed protecting group, perhaps,
(g) be the compound of the halogen-containing formula I of preparation, can be with the formula I compound of corresponding hydroxyl-replacement (R wherein 1Be carboxyl-protecting group) carry out halogenation.And, if desired, again with said blocking group R 1Cracking is removed, perhaps
(h) for preparation contains amino formula I compound, the nitroreduction of the formula I compound that corresponding nitro can be replaced, perhaps
(i) contain group for preparation
Figure 87106838_IMG17
The formula I compound, R wherein 50And R 51Be low alkyl group or represent 5 to 8 yuan of saturated N-heterocycles with nitrogen-atoms, can be with the activity derivatives reaction of the carboxamides derivatives of the corresponding amino compound that replaces amino in the formula I compound and general formula (VII),
Figure 87106838_IMG18
（Ⅶ）
R wherein 50And R 51As defined above, perhaps
(j) for preparing the compound of formula I, wherein R 1Be carboxyl-protecting group, the carboxylic acid of formula I can be carried out corresponding esterification, perhaps
(k) but be the salt of hyoscine of the compound of preparation formula I, hydrate or solvated compounds, perhaps the solvate of said salt or hydrate can change the compound of formula I into salt, hydrate or solvate, perhaps change the hydrate or the solvate of said salt into.Method A:
As mentioned above, required compound can be by the compound of representing with logical formula III, and the amine reaction of representing with logical formula IV obtains,
（Ⅲ）
Wherein, R 1, R 2, R 3, R 4With X with defined above identical, X ' is a halogen atom, the amino of existence, hydroxyl and/or carboxyl can be protected.
（Ⅳ）
Wherein, R 5And R 6With defined above identical, subsequently,, can remove blocking group if be necessary.
In method A, the compound that is used for initiator that formula III is represented is a compounds, and it can be according to, for example following response diagram (a) or (b), prepares.
Figure 87106838_IMG21
Wherein, R 2, R 3, R 4, X and X ' be with previously defined identical; R ' is a blocking group, as benzyl, methoxybenzyl, methoxyl methyl, methoxy (ethoxy) methyl, THP trtrahydropyranyl, allyl group, the tertiary butyl, tertiary butyl dimethylsilyl, ethanoyl, benzoyl or the like; R " be a blocking group, as formyl radical, ethanoyl, trifluoroacetyl group, benzoyl, ethoxycarbonyl, 2,2,2-trichloro-ethoxycarbonyl, carbobenzoxy, carbobenzoxy-(Cbz), tertbutyloxycarbonyl or the like; R " ' be a hydrogen atom or an ethyl.
If the compound of formula IV contains amino or alkyl monosubstituted amino substituting group; then described substituting group; if necessary; can be protected by an amido protecting group; as formyl radical, ethanoyl, trifluoroacetyl group, benzoyl, ethoxycarbonyl, 2; 2,2-trichloro-ethoxycarbonyl, carbobenzoxy, carbobenzoxy-(Cbz), tertbutyloxycarbonyl etc.
The compound of formula III and the amine of formula IV or due care amine between reaction, if necessary, can carry out having under solvent or the solvent-free situation.Preferably at high temperature react time enough so that reaction is complete substantially, the optimal temperature scope is in about 30 ℃ to 200 ℃ scopes, preferably from 80 ℃ to 150 ℃, to obtain enough fast speed of response.
React under the existence that is preferably in acid acceptor and carry out, as triethylamine, pyridine, picoline, N, accelerine, 1,8-diazabicyclo (5.4.0) hendecene-(7), 1,4-diazabicyclo (2.2.2) octane, alkali metal hydroxide, alkaline carbonate or the like.In addition, the amine of also available excessive formula IV is made acid acceptor.
The suitable solvent of this reaction is reactionless active solvent, as acetonitrile, alcohol, dimethyl sulfoxide (DMSO), dimethyl formamide, N,N-DIMETHYLACETAMIDE, pyridine, picoline, lutidine, N, and N '-dimethyl allene urea or the like.The mixture of two or more solvents also can use.
Need, blocking group can be removed after reaction finishes, and the people that the method for removing is familiar with synthetic work is known, as, formyl radical usable acid or basic hydrolysis are preferably removed with basic hydrolysis, and carbobenzoxy-(Cbz) then can be removed by hydrogenolysis.
The starting raw material that formula III is represented can following example:
9,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-benzene and oxadiazine-6-carboxylic acid,
9,10-two chloro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-benzene and oxadiazine-6-carboxylic acid,
9-chloro-10-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-benzene and oxadiazine-6-carboxylic acid, ethyl ester,
9,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-benzene and oxadiazine-6-benzyl carboxylate,
9,10-two fluoro-3-(2-fluoro ethyls)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-benzene and oxadiazine-6-carboxylic acid,
9,10-two fluoro-2,3-dimethyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-benzene and oxadiazine-6-carboxylic acid,
9,10-two fluoro-2-(methylols)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid,
9,10-two fluoro-2-[(dimethylaminos) methyl]-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid,
9,10-two fluoro-2,2,3-trimethylammonium-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid or the like.
The amine of the formula IV of using in above-mentioned reaction is, for example, piperazine, 4-methyl-piperazine, the 3-methylpiperazine, the 3-phenylpiperazine, the 3-(4-aminophenyl)-piperazine, the 3-(4-nitrophenyl) piperazine, the 4-(2-hydroxyethyl) piperazine, morpholine, the 2-methylmorpholine, 2, the 6-thebaine, thiomorpholine, the 4-(aminoethyl) piperidines, 4-((methylamino-) methyl) piperidines, 4-((ethylamino) methyl) piperidines, the 4-amino piperidine, the 4-(methylamino-) piperidines, the 4-(ethylamino) piperidines, 4-(benzyloxy carbonyl amido) piperidines, 4-(carbobenzoxy-(Cbz) methylamino-) piperidines, 4-(carbobenzoxy-(Cbz) ethylamino) piperidines, the 4-hydroxy piperidine, 4-methoxyl group piperidines, the 4-(1-pyrryl) piperidines, high piperazine, 3-((methylamino-) methyl) tetramethyleneimine, 3-((ethylamino) methyl) tetramethyleneimine, the 3-(acetyl aminomethyl) tetramethyleneimine, the 3-hydroxyl pyrrolidine, 3-methoxyl group tetramethyleneimine, the amino pyrrole pyrrole of 3-alkane, 3-(benzyloxy carbonyl amido) tetramethyleneimine, the 3-(methylamino-) tetramethyleneimine, 3-(benzyloxy carbonyl methylamino-) tetramethyleneimine, 3-amino-4-Phenylpyrrolidine, 3-amino-3-methyl-tetramethyleneimine, 3-amino-4-crassitude, 3-(4-aminobenzyl amino) tetramethyleneimine, 3-(4-methyl isophthalic acid-piperazinyl) tetramethyleneimine, 3-((dimethylamino) methene amido) tetramethyleneimine, 3-((methylamino-) methyl)-4-Phenylpyrrolidine, 3-methyl-3-((methylamino-) methyl) tetramethyleneimine, the 3-(ethylamino) tetramethyleneimine, 3-(carbobenzoxy-(Cbz) ethylamino) tetramethyleneimine, the 3-[(dimethylamino) methyl] tetramethyleneimine, the 3-[(ethylmethylamino) crassitude, 3-azido--4-methoxyl group tetramethyleneimine, 3-amino-4-methoxyl group tetramethyleneimine, 3-methoxyl group-4-(methylamino-) tetramethyleneimine, the 3-(ethylamino)-4-methoxyl group tetramethyleneimine, 3-azido--4-hydroxyl pyrrolidine, 3-amino-4-hydroxy tetramethyleneimine, the 3-(methylamino-)-the 4-hydroxyl pyrrolidine, the 3-(ethylamino)-the 4-hydroxyl pyrrolidine, the 3-(aminomethyl)-the 4-crassitude, 3-methyl-4-[(methylamino-) methyl] tetramethyleneimine, the 3-[(ethylamino) methyl]-the 4-crassitude, 3-hydroxyl-4-methoxyl group tetramethyleneimine, the 3-(acetylamino methyl)-the 4-hydroxyl pyrrolidine, imidazoles, 4-methylimidazole, N, N, N '-trimethylammonium ethylene diamine or the like.
Method B:
Required compound can be obtained by carbonyl compound or its polymkeric substance, acetal, ketal or the enol ether reaction that the compound and the logical formula VI of formula (V) expression are represented, subsequently, if necessary, removes protecting group again,
Figure 87106838_IMG23
（Ⅴ）
In the formula V, R 1, R 2, R 5, R 6Identical with X with the front definition; The amino, hydroxyl and/or the carboxyl that exist can be protected.
Figure 87106838_IMG24
（Ⅵ）
In the formula VI, R 3And R 4With previously defined identical, the amino of existence can be protected.
Among the method B, the compound as initiator of formula (V) expression is a compounds, this compound can by above-listed reaction scheme figure a) or b) prepare, or with compound (H) or (V a) is reacted with the amine of formula IV and prepared.
If the carbonyl compound of formula VI; or its polymkeric substance, acetal, ketal or enol ether contain amino or alkyl monosubstituted amino substituting group; need, described substituting group can with previously described in formula (G) and formula (H) R " group under the item is protected.
If desired, reaction can be carried out in solvent, as diox, tetrahydrofuran (THF), acetonitrile, chloroform, dimethyl formamide, dimethyl sulfoxide (DMSO), N, and N '-dimethyl allene urea, acetic acid or the like.Also can use the mixture of two or more solvents.
If desired, reaction can be carried out under acid catalyst.The pyridinium salt of acid catalyst such as acetic acid, hydrochloric acid, sulfuric acid, methylsulfonic acid, tosic acid, tosic acid, iron(ic) chloride, zinc chloride, chloro trimethyl silane, Nafion-H(perfluorinated resin-sulfonic acid; Aldrich chemical company product), Amberlyst-15(strong acid type coarse network resin; Aldrich chemical company produces) or the like.
Temperature of reaction can change in a wide relatively scope.In general, be reflected under the temperature of reaction between 20 ℃ to 150 ℃ and carry out.
Best example by method provided by the invention is: every mole of formula (V) compound uses the formula VI carbonyl compound of about 1 mole or molar excess number, or its polymkeric substance, acetal, ketal or enol ether.
Amino or alkyl monosubstituted amino protecting group if desired, can be removed after reaction.The step of removing is that those people that are familiar with synthetic work know, for example, formyl radical usable acid or basic hydrolysis are removed, and preferably remove with basic hydrolysis, and the carbobenzoxy-(Cbz) available hydrogen is separated and removed.
The initiator of formula (V) expression can following example:
6,7-two fluoro-8-hydroxyl-1-(methylamino-s)-4-oxo-1,4-dihydro-3-quinolinic acid ethyl ester,
6,7-two fluoro-8-hydroxyl-1-(methylamino-s)-4-oxo-1,4-dihydro-3-quinoline acid benzyl ester,
6,7-two chloro-8-hydroxyl-1-(methylamino-s)-4-oxo-1,4-dihydro-3-quinolinic acid,
6-chloro-7-fluoro-8-hydroxyl-1-(methylamino-)-and 4-oxo-1,4-two throwing-3-quinolinic acids,
6,7-two fluoro-1-[(2-fluoro ethyls) amino]-8-hydroxyl-4-oxo-1.4-dihydro-3-quinolinic acid,
6-fluoro-8-hydroxyl-7-(1-imidazolyl)-the 1-(methylamino-)-4-oxo-1,4-dihydro-3-quinolinic acid,
6-fluoro-8-hydroxyl-7-(1-imidazolyl)-the 1-(methylamino-)-4-oxo-1,4-dihydro-3-quinolinic acid ethyl ester,
6-fluoro-8-hydroxyl-7-(1-imidazolyl)-the 1-(methylamino-)-4-oxo-1,4-dihydro-3-quinoline acid benzyl ester,
6-fluoro-1-((2-fluoro ethyl) amino)-8-hydroxyl-7-(1-imidazolyl)-and 4-oxo-1,4-dihydro-3-quinolinic acid,
6-chloro-8-hydroxyl-7-(1-imidazolyl)-the 1-(methylamino-)-4-oxo-1,4-dihydro-3-quinolinic acid,
6-fluoro-8-hydroxyl-1-(methylamino-)-7-(4-methyl isophthalic acid-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinic acid,
7-(3,4-dimethyl-1-piperazinyl)-6-fluoro-8-hydroxyl-1-(methylamino-)-4-oxo-1,4-dihydro-3-quinolinic acid,
7-[3-[(carbobenzoxy-(Cbz) ethylamino) methyl]-the 1-pyrrolidyl]-6-fluoro-8-hydroxyl-1-(methylamino-)-4-oxo-1,4-dihydro-3-quinolinic acid,
The 7-[3-(benzyloxycarbonyl amino)-the 1-pyrrolidyl]-6-fluoro-8-hydroxyl-1-(methylamino-)-4-oxo-1,4-dihydro-3-quinolinic acid,
7-[3-[(carbobenzoxy-(Cbz) methylamino) methyl]-4-methyl isophthalic acid-pyrrolidyl]-6-fluoro-8-hydroxyl-1-(methylamino-)-4-oxo-1,4-dihydro-3-quinolinic acid,
The 7-[3-[(benzyloxycarbonyl amino) methyl]-4-chloro-1-pyrrolidyl]-6-fluoro-8-hydroxyl-1-(methylamino-)-4-oxo-1,4-dihydro-3-quinolinic acid, or the like.
Can be the carbonyl compound of formula VI with the example of the compound of formula (V) compound reaction, as formaldehyde, acetaldehyde, acetone, methyl ethyl ketone or the like; Their polymkeric substance such as Paraformaldehyde 96, Metaldehyde, trioxane or the like; Their acetal such as Methylal(dimethoxymethane), 1,1-glycol dimethyl ether, 1,3-dioxolane, hydroxy-acetaldehyde dimethyl acetal, dimethylamino dimethylacetal or the like; Their ketal is as 2,2-Propanal dimethyl acetal etc.; And their enol ether such as 2-methoxyl group propylene, 2-trimethylsiloxy propylene or the like.
Method C:
Compound (the radicals R wherein for preparing formula I when needs 5R 6N-one contains group-NR 75 to 7 yuan of heterocycles, and R 7Be not hydrogen, group shown in (VIII) formula for example) time, then required compound can be by the compound of formula I (R wherein 7Be hydrogen) and can produce R 70The reagent react of group makes.
Figure 87106838_IMG25
（Ⅷ）
Wherein, piperazinyl can be substituted on its carbon atom, and R 70Be low-grade alkenyl, low alkyl group or aralkyl (they also can be substituted), or the group represented of logical formula II,
(wherein n is from 0 to 4, R 8Be a hydrogen atom, a lower alkoxy or an amino, low alkyl group or aryl, they also can be substituted).
This reaction, i.e. N-alkylation (or N-acidylate), can finish by following route:
The N-alkylation:
The compound of general formula (IX)
Figure 87106838_IMG26
（Ⅸ）
(R wherein 1, R 2, R 3, R 4With X with previously defined identical, piperazinyl can be substituted on carbon atom, and the amino, hydroxyl and/or the carboxyl that exist can be protected) can with
(1) compound with general formula (X) expression reacts
R 70-Y （Ⅹ）
Wherein, Y is a leavings group, R 70With previously defined identical,
Perhaps, (in order to obtain R 7Be R 9CO-CH 2CH 2-compound)
(2) the Michael's receptor with general formula (XI) reacts
Wherein, R 9Be a low alkyl group or a lower alkoxy,
Perhaps, (in order to obtain R 7Compound for methyl or sulphur methyl)
(3) with formaldehyde and a formic acid or a basic metal bisulfite reaction.
The N-acidylate
The compound of above-mentioned formula (IX) can with the anhydride reaction of general formula (XII), to form formula I compound, wherein R 7Be HOOC-Z-CO-
Figure 87106838_IMG27
（Ⅻ）
In the formula XII, Z is the chain alkylene that replaces of can having that contains 2-3 carbon atom, or inferior aryl.
All these reactions if desired, can be removed protecting group (if having protecting group) subsequently again.
So required compound can be by reacting the compound of formula (IX) representative and the compound of formula (X) representative.As having that leavings group Y can mention, for example, halogen atom such as chlorine, bromine, iodine; Acyloxy is such as acetoxyl group; The low alkyl group sulfonyloxy is such as mesyloxy; Aryl-sulfonyl oxygen is such as tolysulfonyl oxygen base; Can nitrated arbitrarily phenoxy group such as phenoxy group, 4-nitrophenoxy; Perhaps succimide oxygen base or phthalic imidine oxygen base.
If the compound of formula (X) contains amino or alkyl monosubstituted amino substituting group, then, if desired, described substituting group can be by-group, such as above-mentioned in formula (G) and (H) R " group under is protected.
If desired, reaction can be carried out in a kind of solvent, as dimethyl formamide, N,N-DIMETHYLACETAMIDE, dimethyl sulfoxide (DMSO), N, and N '-dimethyl allene urea, diox, tetrahydrofuran (THF), pyridine or the like.Also can be with the mixture of two kinds or multiple solvent.
React under the existence that is preferably in acid acceptor and carry out, as triethylamine, pyridine, N, accelerine, 1,4-diazabicyclo (2.2.2) octane, 1,8-diazabicyclo (5.4.0)-+-carbene-(7), sodium hydride, alkali metal hydroxide, alkaline carbonate or the like.
Temperature of reaction can change in the relative broad range relatively.In general, be reflected between about 0 ℃ to 180 ℃ and carry out, preferably between 0 ℃ to 110 ℃.By method provided by the invention, the compound of per 1 mole formula (IX) can be with 1 to 4 mole, and preferably the compound of 1 to 2 mole formula (X) reacts.
The compound that is used for formula of the present invention (X) can be: methyl iodide; iodoethane; monobromethane; the 1-butyl iodide; the 1-n-butyl bromide; propyl iodide; 2-iodopropane; 1-fluoro-2-iodoethane; 1-iodo-2-methyl ethyl ether; N-(2-iodine ethyl) ethanamide; N-(2-iodine ethyl)-the N-methylacetamide; bromoacetic acid; allyl bromide 98; the 4-fluoro benzyl bromide; the acetate formic anhydride; diacetyl oxide; Acetyl Chloride 98Min.; propionic anhydride; propionyl chloride; benzoyl oxide; Benzoyl chloride; 4-((trifluoroacetyl group) amino) benzoyl oxide; monochloroacetone; 1-chloro-2-butanone; phenacyl chloride; 4-acetylamino phenyl-chloromethyl ketone; Vinyl chloroformate; methyl-chloroformate; chloromethyl-4-nitrophenyl ketone; 4-nitrobenzyl bromine; dimethylaminoethyl chloride or the like.
Perhaps, required compound also can be by making the compound of formula (IX) and Michael's receptor reaction of formula (XI).
If desired, this reaction can be reacted in a kind of solvent, as, dimethyl formamide, N,N-DIMETHYLACETAMIDE, methyl-sulphoxide, diox, tetrahydrofuran (THF), methyl alcohol, ethanol, propyl alcohol, ethylene glycol monomethyl ether or the like.The also mixture of available two or more solvents.
Temperature of reaction can change in the relative broad range relatively.In general, be reflected between about 30 ℃ to 170 ℃ and carry out, preferably between 50 ℃ to 140 ℃.
By method provided by the invention, the compound of per 1 mole formula (IX) better is and the 1-5 mole preferably to use the compound reaction of the formula (XI) of 1-2 mole.
The used Michael's receptor of the present invention can be, for example, and methyl vinyl ketone, ethyl vinyl ketone or the like.
The compound of formula (IX) and formic acid and formaldehyde or-reaction of basic metal hydrosulphite (obtains wherein R 7Formula I compound for methyl or sulphur methyl) normally under slightly high temperature, carry out, as, between approximately+50 ℃ to+100 ℃.
And required compound also can be by making the compound of formula (IX) and the anhydride reaction of formula (XII).
If necessary, reaction can be carried out in a kind of solvent, as pyridine, dimethyl formamide, dioxane, tetrahydrofuran (THF) or the like.Also can use the mixture of two kinds or more solvent.
React under the existence that is preferably in acid acceptor and carry out, as triethylamine, pyridine, N, accelerine, 1,4-diazabicyclo (2.2.2) octane, alkali metal hydroxide, alkaline carbonate or the like.
Temperature of reaction can change in the relative broad range relatively.In general, reaction can be carried out in the temperature between about 0 ℃ to 120 ℃, preferably between 0 ℃ to 100 ℃.
When reacting by method provided by the invention, the compound of the compound of every mole of formula (IX) the most handy 1 mole or excessive formula (XII).
Used acid anhydrides among the present invention, for example, Succinic anhydried, Pyroglutaric acid, N-carbobenzoxy-(Cbz)-aspartic anhydride, N-carbobenzoxy-(Cbz) L-glutamic acid acid anhydride, Tetra hydro Phthalic anhydride etc.
If desired, blocking group can be after reaction be proficient in the method that the synthetic people are familiar with by some and be removed.For example, formyl radical can be by acid hydrolysis or basic hydrolysis, and preferably basic hydrolysis is removed, and carbobenzoxy-(Cbz) can be removed with the hydrogenolysis method.
Removing of protecting group can be finished before or after isolating product.
Method D:
Compound [wherein, the R for preparing formula I when needs 5And/or R 6Be low alkyl group, (or containing a two elementary alkyl amido or lower alkoxy)] time, these compounds can by will corresponding non-alkylating compound (promptly in formula I, R 5And/or R 6Be hydrogen or contain an amino, low-grade alkyl amino or hydroxyl) carry out low alkyl groupization and make.The N-alkylated reaction can react by the compound with general formula (X III) and carry out.
Wherein, R 10Be low alkyl group, Y is a leavings group.This leavings group is identical with the type of using in formula (X) compound.And reaction can be carried out the alkylating reacting phase of compound (IX) mode together by aforesaid usefulness (X).The O-alkylation can be carried out as the N-alkylation; Yet, need suitably add proton acceptor such as alkalimetal hydride, as sodium hydride.
Method E:
As needs preparation R in formula I 5R 6N-be-contains-SO-or-SO 2-5 to 7 membered heterocyclic compounds the time, these compounds can promptly have in heterocycle by the non-oxygen compound of the corresponding formula I of oxidation-the anaerobic thing of S-part makes.
Oxidation can be undertaken by handling with inorganic or organic oxidizing agent.The various oxygen-generating compounds that are easy to can be used as oxygenant very much; For example: organo-peroxide, such as mono-substituted organo-peroxide (as, C 1-C 4-alkyl-or alkyloyl-hydroperoxide, such as tert-butyl hydroperoxide); Peroxyformic acid and peracetic acid, and the phenyl substituted derivative of these hydroperoxide are such as cumene hydroperoxide and benzoyl hydroperoxide.If desired, phenyl substituent can have-group of even lower level is (as a C 1-C 4Alkyl or alkoxyl group) ,-halogen atom or-carboxyl (as, 4-methyl-benzoyl hydroperoxide, 4-methoxyl group-benzoyl hydroperoxide, 3-chloroperoxybenzoic acid and monoperphthalic acid).Various inorganic oxidizer also can be used for as oxidising agent; For example, hydrogen peroxide, ozone, permanganate such as potassium permanganate or sodium permanganate, hypochlorite be such as hypochlorous sodium salt, sylvite or ammonium salt, permonosulphuric acid and peroxide pyrosulfuric acid.With the 3-chloroperoxybenzoic acid is preferred.Oxidation is carried out favourable in inert solvent.For example, in non-proton property inert solvent, such as tetrahydrofuran (THF), dioxane, methylene dichloride, chloroform or ethyl acetate.Oxidizing reaction is generally carried out in-20 ℃ to+50 ℃ these temperature ranges.
When oxygenant is compared with equimolar amount or excessive slightly the reaction with initiator, mainly obtain corresponding sulfoxide, that is, in formula I, contain-heterocycle of SO-.When the amount of oxygenant is increased to 2 times of stoichiometric ratio or more for a long time, obtain corresponding sulfone, promptly in formula I, have-SO 2-heterocycle.Also might be from corresponding sulfoxide by preparing sulfone with equivalent or excessive oxidizer treatment.
Method F:
When desire prepares the compound that contains free amine group, hydroxyl and/or carboxyl in the formula I, these compounds can from containing of corresponding formula I one or more arbitrary amino, hydroxyl and/or carboxyls that exist with the protection form compound prepare.
Amino protecting group is that for example, low-grade alkane acidyl is such as ethanoyl; Benzoyl;-carbalkoxy is as tertbutyloxycarbonyl or ethoxycarbonyl; The carbalkoxy of-replacement is as trichloro-ethoxycarbonyl; Carbobenzoxy; Carbobenzoxy-(Cbz); Right-the nitro carbobenzoxy-(Cbz);-aralkyl is as trityl, diphenyl-methyl; Perhaps halogen-alkyloyl is as trifluoroacetyl group.
The removing usable acid hydrolysis (as tertbutyloxycarbonyl or trityl) or remove of amino protecting group with basic hydrolysis (as trifluoroacetyl group).Carbobenzoxy-(Cbz) and right-nitro carbobenzoxy-(Cbz) available hydrogen solution are removed.
Can preferably under low-grade alkyl carboxylic acid's help, be removed by the amino protecting group that the acid-hydrolysis method cracking is removed.This carboxylic acid can be by halogenation.Preferably use formic acid or trifluoroacetic acid.Acid hydrolysis generally is at room temperature to carry out, although also can be high slightly or carry out (as about 0 ℃ to+40 ℃ of temperature range) slightly under the low temperature.The blocking group that can be cleaved under alkaline condition falls general with rare caustic-alkali aqueous liquid 0 ℃ to 30 ℃ hydrolysis.
Carboxyl-protecting group is, for example the front at R 1The carboxyl-protecting group of discussing under.
Remove these protecting groups and can use known method, as hydrogenation (benzyl) or acid hydrolysis, basic hydrolysis.The reaction be preferably in the inert solvent, temperature about 0 ℃ to carrying out between the room temperature.Special narrow spectrum method also is useful, as, to a nitrobenzyl, in the presence of S-WAT, in approximately or be lower than 0 ℃ to room temperature, hydrolysis is removed under the condition of solvent such as dimethyl formamide (aqueous solution); The tertiary butyl can be by in the presence of methyl-phenoxide, about 0 ℃ to room temperature, usefulness or remove without reacting with trichoroacetic acid(TCA) under the condition of cosolvent (as methylene dichloride); Or 4, allyl group can be removed by the catalytic allyl group shift reaction in the presence of 2 ethyl hexanoic acid sodium or its sylvite of palladium.Example referring to " organic chemistry magazine " 1982,47,587.
Method G:
When desire preparation contains the formula I compound of halogen atom (as, R wherein 5R 6N-is
Figure 87106838_IMG28
), this compound can by with corresponding hydroxyl substitution compound (as, R wherein 5R 6N-is
Figure 87106838_IMG29
) halogenation makes.Halide reagent is thionyl halide preferably, particularly thionyl chloride; Or phosphorus trichloride, phosphoryl chloride or phosphorus pentachloride.Temperature of reaction is preferably between about 0 ℃ to 80 ℃.The carboxyl that exists preferably protected, for example benzylization.Then, if desired, make it dissociate out by for example hydrogenation (removing benzyl) again.
Method H:
When the desire preparation contains the formula I compound of an amino (such as R in compound 5R 6N-is
Figure 87106838_IMG30
) time, this compound can pass through the nitroreduction with the formula I compound of corresponding nitro replacement.Reduction reaction can be carried out with hydrogenation under noble metal catalyst such as the catalysis of palladium charcoal.Reaction can be carried out in water and lower alcohol such as methyl alcohol or ethanol preferably, if desired, and the mixture of also available other soluble solvent composition in this solvent.Temperature of reaction usually between about 10 ℃ to 40 ℃, best about room temperature.
Method I:
When the desire preparation contains
Figure 87106838_IMG31
The formula I compound of group (R wherein 50, R 51With preceding identical), for example work as R 5R 6N-is (CH 3) 2N-CH=
Figure 87106838_IMG32
) compound, this compound can make by following this method: with the amino-substituted compounds of corresponding formula I (as R wherein 5R 6N-is H 2N
Figure 87106838_IMG33
) amino and the reactive derivative form reaction of the carboxamides derivatives of general formula (VII)
（Ⅶ）
Wherein, R 50And R 51As mentioned above.
Can use the corresponding aldehyde pure form of two (low alkyl groups) that contracts as the activated derivatives of the compound of formula VII, as methylal.Reaction is preferably carried out in inert solvent such as Anaesthetie Ether, dimethyl formamide or dimethyl sulfoxide (DMSO).Temperature of reaction is preferably in about room temperature, but also can be higher or low, can be about 0 ℃ to 100 ℃ as temperature range.
Method J:
The ester of preparation formula I, i.e. R wherein 1Be-carboxyl-protecting group, can be by acid and corresponding halogenide with formula I, preferably iodide or bromide (it contains required ester group part) reaction makes.Reaction can be quickened under the help of alkali, and alkali can be for example alkali metal hydroxide, alkaline carbonate or organic amine such as triethylamine.Esterification is preferably in the inert organic solvents, as N,N-DIMETHYLACETAMIDE, HMPA, dimethyl sulfoxide (DMSO), or particularly carries out in dimethyl formamide.Temperature of reaction is preferably in about 0 ℃ to 40 ℃ this scope.
Method K:
But the salt of the hyoscine of the compound of preparation formula I or the hydrate or the solvate of said salt, can carry out with known method, as required alkali reaction with carboxyl in the formula I and equivalent, otherwise or, with the free alkali and the organic or inorganic acid-respons of formula I.Reaction can be carried out as (as ethanol, methyl alcohol, propyl alcohol etc.) in water or the organic solvent in solvent easily.The temperature of reaction that salt generates is not strict, generally at room temperature gets final product salify, can be 0 ℃ to+50 ℃ as temperature range high slightly or be lower than slightly under the room temperature and carry out yet.
The example of the useful acid that can be used for treating has in above-mentioned steps: hydrochloric acid, Hydrogen bromide, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetate, propionic acid, Succinic Acid, oxyacetic acid, lactic acid, oxysuccinic acid, tartrate, citric acid, xitix, toxilic acid, hydroxymaleic acid, toluylic acid, phenylformic acid, the 4-benzaminic acid, anthranilic acid, the 4-hydroxy-benzoic acid, Whitfield's ointment, aminosallcylic acid, nicotinic acid, methylsulfonic acid, ethyl sulfonic acid, ethylenehydrinsulfonic acid, Phenylsulfonic acid, right-toluenesulphonic acids, glyconic acid, glucuronic acid, galacturonic acid, aspartic acid and L-glutamic acid; Methionine(Met), tryptophane, Methionin, arginine etc.
The salt of acid addition can change into free form by handling with alkali (such as metal hydroxides, ammonia etc.).
The alkali salt of the compound of formula I can be by with formula I compound and a metal base or amine, as basic metal or alkaline earth metal hydroxides or-organic amine reacts and makes.As the metal that positively charged ion uses, example has sodium, potassium, magnesium, calcium etc.The example of amine has: diethanolamine, N, N '-dibenzyl ethylene diamine, choline, 1 etc.
The acid salt of the compound of formula I or alkali salt are different from its corresponding free form aspect the solubleness in as water on some physical propertiess.
But the salt of the compound of formula I and their hyoscine can be with solvation or the form of solvation not, comprise that the form of hydration exists.Hydration can be in preparation process takes place automatically, or takes place gradually as the result of the hygroscopic nature of initial anhydrous compound.For controlledly preparing hydrate, anhydrous fully or the anhydrous compound of part can be exposed in the moist atmosphere (as approximately+10 ℃ to+40 ℃).But can when carrying out, obtain as crystallisation process with the solvent of hyoscine such as the solvate of ethanol formation.
Has center of asymmetry by some compound provided by the invention.Pure D isomer, pure L isomer with and composition thereof (comprising racemic mixture) also among consideration of the present invention.
According to compound provided by the present invention, shown widely gram-positive bacteria, gram-negative bacteria to be reached the anti-microbial activity of a former bacterium, thereby can be as the reagent of treatment and prophylaxis against infection diseases.It is as follows to reach antibacterial activity in vitro in the body of these compounds of the present invention:
1, antibacterial activity in vitro:
Representative pyrido of the present invention (3,2,1-ij)-1,3, the antibacterial activity in vitro of 4-Ben Bing oxadiazine derivative is to measure with the agar dilution of standard.(referring to Chemotherapy, 22 1126(1974)).Their minimum inhibition concentration (MIC represents with mcg/ml) sees table 1 and table 2.Here used compound is to prepare in the example of mentioning respectively below.
Figure 87106838_IMG35
Figure 87106838_IMG36
Figure 87106838_IMG38
Table 2
Antimicrobial spectrum MIC(mcg/ml)
Compound (routine number)
Anaerobion 5 30
Fragility bacteroid ATCC 23,745 0.78 0.20
Fragility bacteroid NR 2,579 3.13 1.56
Fragility bacteroid NR 2,582 0.78 0.39
Fragility bacteroid NR 2,583 0.39 0.10
Fragility bacteroid NR 2,584 0.78 0.78
Bacteroides????distasonis????NR2578????0.78????0.78
Bacteroides????thetaiotaomicron
NR????2588????1.56????0.78
Counterincision in pubescence bacterium
ATCC????15703????0.39????0.10
Clostridium botulinum NR 2,611 0.10 0.013
Aerogenesis capsule bacillus NR 2,612 0.39 0.10
The moniliform clostridium
ATCC????25546????0.78????0.10
Variant fusiform bacilarmature ATCC 8,501 12.5-
Peptococcus????prevotii????ATCC????9321????1.56????0.39
Peptone coccus variant
ATCC????14955????0.78????0.20
peptostreptococcus????anaerobius
NR????2743????0.39????0.013
Propionibacterium acnes
ATCC????11828????0.78????0.78
Mycoplasma
Human body props up former bacterium NR 2,952 0.10 0.10
2, cylinder therapeutic effect
The pyrido (3 that following example 5, example 30, example 65 and example 66 make, 2,1-ij)-1,3, the antibacterial activity in vivo of 4-Ben Bing oxadiazine derivative is to use intestinal bacteria ML4707, and the deadly infection that edge purulence bacillus 4au542 and streptococcus pneumoniae 6-001 cause is measured.Heavily about 20 grams of ICR mouse, peritoneal injection corresponding bacteria suspension are to cause infection.Oral or the subcutaneous injection administration with testing compound.Observe 5 days death toll.Medium lethal dose (the ED of each compound 50, milligram/kilogram), promptly protect half animal to avoid listing in table 3 respectively because of infecting dead dosage.
Table 3
Antibacterial activity in vivo (ED to the mouse systemic infection 50Milligram/kilogram)
Bacterium
Compound intestinal bacteria ML4707 Pseudomonas aeruginosa 4au542 streptococcus pneumoniae 6-001
Subcutaneous oral oral
Example 5 0.06 0.11 13.4 10.3
Example 30 0.10 0.62 57.0 65.9
Example 65-1.12--
Example 66-0.51--
3, acute toxicity
The LD separately of the compound that from example 5,6,7,16,17,18,30,36 and 56, obtains cited below 50Value is all greater than 2000 milligrams/kilogram.The acute toxicity of these compounds is by measuring ICR mouse oral administration.
These compound exhibits provided by the invention to the broad spectrum antibiotic activity of gram-positive bacteria, gram-negative bacteria and mycoplasma.Particularly to those to various antibiotic, as penicillins, cephalosporins, aminoglycosides, tetracyclines etc., drug-fast bacterium is taken place also anti-microbial activity.
In addition, compound provided by the invention has low toxicity, potent and wide spectrum anti-microbial effect.The provide protection to mouse whole body infectation of bacteria of compound of the present invention is better than those synthetic antibacterial agents that can buy on market.Therefore, compound of the present invention can effectively be used for preventing or treat the disease that causes in human body or the intravital Ge Shi positive bacteria of animal, Ge Shi negative bacterium and bacterium sample microorganism.
For example, can treat and/or prevent because the disease that following microorganism or their mixture cause: staphylococcus, suis, aerobic coccus (AeroCoccus), faecalis, micrococcus, lactobacillus, the counterincision bacterium, clostridium, fungi, peptone coccus (Peptococcus), Peptostreptococcus, bacterium acidi propionici, intestinal bacteria, Citrobacter, Campylobacter, the intestines bacterium, Klebsiella pneumoniae, Bacillus proteus, pseudomonas, Serratia, Salmonellas, shiga bacillus, vibrios, Aeromonas, influenzae, Neisseria, Acinetobacter, Alcaligenes, bordetella, genera bacillus, fusiform bacilarmature, mycoplasma and other microorganism.
The invention further relates to the pharmaceutical composition that contains the compound among one or several the present invention.
Compound of the present invention can pass through the oral or non-oral administration of various administering modes easily to the human or animal.
And, according to the present invention, compound can use separately or use with compositing formulas such as auxiliary, liquid diluent, wedding agent, lubricant, wetting agents, as with the form of pharmaceutical composition, such as tablet, granule, sugar coated tablet, pulvis, capsule, gelifying agent, dry syrup, syrup, ampoule, suspension agent, solution, emulsion, salve, paste, creme, suppository etc.
In addition, dissolving delayed-action activator, short absorption agent, tensio-active agent etc. also can be used as other additive in the prescription,, but can use the formulation of any hyoscine that is.
Can use separately according to compound of the present invention, perhaps use as the mixture of two or more different sorts compounds, the amount of compound accounts for 0.1% to 99.5% of whole pharmaceutical composition weight greatly, and preferably 0.5% to 95%.
Can be deployed into the compound prescription of compound of the present invention according to pharmaceutical composition of the present invention, or with other suitable formulated mixture of the compound that pharmaceutical activity is arranged.
This new compound of the present invention to each patient every day dosage can according to individual instances, animal species, body weight, and the difference of desire treatment situation change, but generally be in 0.5 to 500 milligram of/kilogram weight scope, preferably greatly about 1 to 300 milligram.
Following example is understood the best way of the compound among preparation the present invention specifically.
The preparation of starting raw material
With reference to example
N-(3,4) preparation of aminomethylene diethyl malonate-two fluoro-2-hydroxy phenyls).
(a) with 500 milligram 2,3-two fluoro-6-nitrophenolss are dissolved in 7 ml methanol, go up hydro-reduction 6 hours in 60 milligrams of 5%Pd/C.Reaction mixture is filtered under nitrogen gas stream, and filtrate gets 414 milligrams of thick 2-amino-5, the 6-difluorophenol in decompression evaporation down.
(b) mixture with above-mentioned amine (414 milligrams) and ethoxy methylene diethyl malonate (618 milligrams) heated 5 minutes in 130 ℃ in nitrogen, the crystalloid resistates that generates grinds with ethanol, filter, promptly get 590 milligrams of N-(3,4-two fluoro-2-hydroxy phenyls) the aminomethylene diethyl malonate.Molten some 178-180 ℃; Mass spectrum m/z315(M +).Mother liquor is made eluent with the capable column chromatography of silica gel with chloroform/acetone (20: 1), can obtain additional 59 milligrams of crystallizations.
8-benzyloxy-6, the preparation (route 1) of 7-two fluoro-4-hydroxyl-3-quinoline carboxylic acid ethyl esters
(c) in N-(3,4-two fluoro-2-hydroxy phenyls) in the mixture of aminomethylene diethyl malonate (80 milligrams) and Anhydrous potassium carbonate (70 milligrams) and dry dimethyl formamide (1.5 milliliters), add bromotoluene (30 microlitre).This mixture was stirred under room temperature 2 hours, behind the pressure reducing and steaming solvent, residue is dissolved in the methylene dichloride, filter out precipitation, filtrate water is washed, and uses anhydrous sodium sulfate drying again, then evaporation.The crystalloid resistates washs with normal hexane, uses recrystallizing methanol, gets N-(2-benzyloxy-3, the 4-difluorophenyl)-aminomethylene diethyl malonate (90 milligrams).87 ℃ of fusing points; Mass spectrum m/z405(M +).
(d) with the solution of above-mentioned malonic ester (280 milligrams) in phenyl ether (2.8 milliliters) in nitrogen atmosphere, in 250 ℃ the heating 30 minutes.After the reaction mixture, boil off the ethanol that in reaction medium, produces down in decompression.The dark brown solution that the obtains silicagel column (10 gram) of packing into is used benzene, methylene dichloride and methylene dichloride/acetone (30: 1) wash-out one by one then respectively.Merge pure component, the pressure reducing and steaming solvent obtains crystalline residue.With of the mixing solutions washing of this resistates, get 90 milligrams of 8-benzyloxies-6,7-two fluoro-4-hydroxyl-3-quinoline carboxylic acid ethyl esters with normal hexane and ethyl acetate.Can make-analytic sample 200～201 ℃ of fusing points with recrystallizing methanol; Mass spectrum m/z 359(M +).
8-benzyloxy-6, the preparation (route 2) of 7-two fluoro-4-hydroxyl-3-quinoline carboxylic acid ethyl esters
In 300 milligram 6,7-two fluoro-4,8-dihydroxyl-3-quinoline carboxylic acid ethyl ester add 308 milligrams of Anhydrous potassium carbonates and 145 microlitre benzyl chlorides successively in the stirred solution of 6 milliliters of dimethyl formamides.Mixed solution stirred 11 hours at 55～65 ℃.Then with reaction mixture with 30 ml waters dilutions and use chloroform extraction.Extracting solution with anhydrous sodium sulfate drying after, concentrating under reduced pressure.Residue is made eluent with silica gel (7 gram) column chromatography with acetone/chloroform (1: 20), gets 113 milligrams of 8-benzyloxies-6,7-two fluoro-4-hydroxyl-3-quinoline carboxylic acid ethyl esters.Can make an analytic sample with recrystallizing methanol.200～201 ℃ of fusing points; Mass spectrum m/z 359(M +).
8-benzyloxy-6,7-two fluoro-1-(formyl-methylamino-s)-4-oxo-1, the preparation of 4-dihydro-3-quinoline carboxylic acid ethyl ester
(e) with 410 milligrams of 8-benzyloxies-6,7-two fluoro-4-hydroxyl-3-quinoline carboxylic acid ethyl esters and the mixture of 315 milligrams of Anhydrous potassium carbonates in 10 milliliters of dry dimethyl formamides are after stirring 3 hours under the room temperature, add 260 milligrams of O-(2, the 4-dinitrophenyl) azanol.With mixture room temperature restir 6.5 hours.After removing solvent under reduced pressure, in residue, add 12 ml waters, again mixed solution was stirred under room temperature 3 hours.Filter the collecting precipitation thing, successively wash precipitation, get 405 milligrams of 1-amino-8-benzyloxies-6,7-two fluoro-4-oxos-1,4-dihydro-3-quinoline carboxylic acid ethyl ester with cold water and ether.Can make analytic sample with recrystallizing methanol, fusing point 143-144 ℃; Mass spectrum m/z 374(M +).
(f) 0.60 milliliter 98% formic acid is joined under 0 ℃ in 1.51 milliliters of aceticanhydrides, mixture was stirred 15 minutes in 0 ℃, stirred 15 minutes down at 50 ℃ again, be chilled to 0 ℃ then.Above-mentioned amine (400 milligrams) is splashed in this solution at 2.1 milliliter 98% formic acid solution.Mixed solution in stirring at room 2 days, is carried out reduction vaporization with this reaction mixture then, a crystalline residue, behind ethyl alcohol recrystallization, obtain 410 milligrams of 8-benzyloxies-6,7-two fluoro-1-(formamido-s)-4-oxo-1,4-dihydro-3-quinoline carboxylic acid ethyl ester.188～190 ℃ of fusing points; Mass spectrum m/z402(M +).
(g) mixture that above-mentioned methane amide (400 milligrams), Anhydrous potassium carbonate (275 milligrams) and anhydrous dimethyl formamide (17 milliliters) are formed was in stirring at room 1.5 hours.0.19 milliliter of methyl iodide is joined in this mixed solution, and restir 2.5 hours, removing solvent under reduced pressure, residue distributes between chloroform and water two-phase.The organic layer anhydrous sodium sulfate drying is evaporated to dried then.The residue ethyl alcohol recrystallization gets 335 milligrams of 8-benzyloxies-6,7-two fluoro-1-(formyl methylamino-s)-4-oxo-1,4-dihydro-3-quinoline carboxylic acid ethyl ester.180～181 ℃ of fusing points; Mass spectrum m/z416(M +).
6,7-two fluoro-8-hydroxyl-1-(methylamino-s)-4-oxo-1,4-dihydro-3-quinoline carboxylic acid's preparation
(h) 330 milligrams of 8-benzyloxies-6,7-two fluoro-1-(formyl methylamino-s)-4-oxo-1,4-dihydro-3-quinoline carboxylic acid ethyl ester is in 14 milliliters of chloroforms, and hydrogenation is 4 hours in 50 milligrams of 5%Pd/C.Reaction mixture dilutes with 14 ml methanol, filters then.Filter cake washs with methyl alcohol/chloroform (1: 1).Merging filtrate and evaporation, the residue ethyl alcohol recrystallization gets 239 milligram 6,7-two fluoro-1-(formyl methylamino-s)-8-hydroxyl-4-oxo-1,4-dihydro-3-quinoline carboxylic acid ethyl ester.221～225 ℃ of fusing points (decomposition); Mass spectrum m/z 326(M +).
(i) mixed solution of above-mentioned ester (210 milligrams) with 5.2 milliliters of 0.5N sodium hydroxide heated 2 hours in 100 ℃ in nitrogen atmosphere.Reaction mixture is with 0.16 milliliter of acidifying with acetic acid, and sedimentation and filtration, washing and dry down in decompression with separating out obtain 168 milligram 6,7-two fluoro-8-hydroxyl-1-(methylamino-s)-4-oxo-1,4-dihydro-3-quinoline carboxylic acid.Can get analytic sample through ethyl alcohol recrystallization, 248～250 ℃ of fusing points (decomposition); Mass spectrum m/z270(M +).
Example 1
9,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-carboxylic acid
To in reference example i, make 6,7-two fluoro-8-hydroxyl-1-(methylamino-s)-and 4-oxo-1, the mixture of 4-dihydro-3-quinoline carboxylic acid (105 milligrams), Paraformaldehyde 96 (150 milligrams) and dry dioxane (5 milliliters) heated 3 hours in 100 ℃ under nitrogen atmosphere.Behind the pressure reducing and steaming solvent, add 20 milliliters of dimethyl formamides in the residue and mixture was stirred 20 minutes and after-filtration.Filter cake is washed with dimethyl formamide, and the filtrate of merging is carried out reduction vaporization, and the residue water grinds, and filters then, get 97 milligram 9,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.Carry out recrystallization with dimethyl formamide and can get analytic sample.290～292 ℃ of fusing points (decomposition); Mass spectrum m/z282(M +).
Example 2
9,10-two fluoro-2,3-dimethyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-benzene and oxadiazine-6-carboxylic acid
With make among the reference example i 6,7-two fluoro-8-hydroxyl-1-(methylamino-s)-and 4-oxo-1, the mixed solution that 4-dihydro-3-quinoline carboxylic acid (50 milligrams), 90% acetaldehyde (1 milliliter) and diox (5 milliliters) are formed heated evaporation reaction mixture under decompression 3 hours in 100 ℃ under nitrogen atmosphere, promptly get 52 milligram 9,10-two fluoro-2,3-dimethyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.285～289 ℃ of fusing points; Mass spectrum m/z296(M +).
Example 3
9,10-two fluoro-2-(methylols)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-carboxylic acid
With 50 milligram 6 that makes among the reference example i, 7-two fluoro-8-hydroxyl-1-(methylamino-s)-and 4-oxo-1, the glycolaldehyde diethyl acetal of 4-dihydro-3-quinoline carboxylic acid, 45 microlitres and the pyridinium salt of 7 milligrams of right-toluenesulphonic acidss formed suspension in 2 milliliters of dry dioxanes heated 5 hours in 110 ℃ under nitrogen atmosphere.Remove solvent under reduced pressure, crystalline resistates is water and methanol wash respectively, gets 52 milligram 9,10-two fluoro-2-(methylols)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-benzene and oxadiazine-6-carboxylic acid.254～258 ℃ of fusing points (decomposition); Mass spectrum m/z 312(M +).
Example 4
9,10-two fluoro-2-((dimethylamino) methyl)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-benzene and oxadiazine-6-carboxylic acid tosilate
With 6 of 50 milligrams of making among the reference example i, 7-two fluoro-8-hydroxyl-1-(methylamino-s)-4-oxo-1, the suspension that 4-dihydro-3-quinoline carboxylic acid, 37 milligrams of dimethylamino acetaldehyde reduction methanols and 53 milligrams of tosic acid monohydrates form in 2 milliliters of dioxs under nitrogen atmosphere in 110 ℃ of heating 17 hours.The pressure reducing and steaming solvent, the residue recrystallizing methanol, 61 milligrams 9,10-two fluoro-2-((dimethylamino)-methyl]-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid is right-tosylate.232～236 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z340(MH +).
Example 5
9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-and 7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-carboxylic acid
With 30 milligram 9 that makes in the example 1,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the mixture of 4-benzodiazine-6-carboxylic acid, 47 microlitre N methyl piperazines and 3 milliliters of dry pyridine compositions heated 9 hours in 100～110 ℃ under nitrogen gas stream.The pressure reducing and steaming pyridine, the residue recrystallizing methanol gets 23 milligrams of 9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyls)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.268～269 ℃ of fusing points (decomposition); Mass spectrum m/z 362(M +).
According to making following compounds with example 5 similar methods:
Figure 87106838_IMG41
Example R 5R 6N-fusing point ℃ recrystallization solvent mass spectrum m/z
6
Figure 87106838_IMG42
240～245(decomposes) MeOH 349(MH +) *
7
Figure 87106838_IMG43
237～239(decomposes) MeOH/CHCl 3362(M +)
8 256～259(decomposes dimethyl formamide 425(MH +) *
9
Figure 87106838_IMG45
＞300 EtOH/CHCl 3349（M +）
10
Figure 87106838_IMG46
＞300 dimethyl formamide 377(M +)
11
Figure 87106838_IMG47
＞300(decomposes) dimethyl formamide 365(M +)
12
Figure 87106838_IMG48
238～242(decomposes) MeOH 377(MH +) *
13
Figure 87106838_IMG49
256～258 MeOH/CHCl 3363（M +）
14
Figure 87106838_IMG50
272～274(decomposes) EtOH 413(MH +) *
* fast atom bombardment(FAB)-mass spectrum
Example 24
9-fluoro-3-methyl-7-oxo-10-(3-oxo-1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
With 40 milligram 9 that makes in the example 1,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, 31.1 milligrams of 2-piperazine ketone, 31.8 milligram 1, the mixture that 4-diazabicyclo-(2.2.2) octane and 1 milliliter of dry dimethyl sulfoxide (DMSO) are formed under nitrogen gas stream in 130 ℃ of heating 28.5 hours.The pressure reducing and steaming solvent.Residue is with preparing the pure system of thin-layer chromatography (silica gel: chloroform/methanol 10: 1.5), again through methylene dichloride and methanol mixed solvent recrystallization, get 6.3 milligrams of 9-fluoro-3-methyl-7-oxo-10-(3-oxo-1-piperazinyls)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.Fusing point＞300 ℃; Fast atom bombardment(FAB)-mass spectrum m/z 363(MH +).
Following several compound can be begun by the compound described in example 2,3 and 4, according to making with example 5 similar methods:
Figure 87106838_IMG53
Example 29
The 10-[3-(benzyloxycarbonyl amino)-the 1-pyrrolidyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-carboxylic acid
With make in the example 19,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid) 28 milligrams), 94 milligrams of 3-(benzyloxycarbonyl aminos)-mixture that Pyrrolidine and 3 milliliters of dry pyridines are formed under nitrogen gas stream in 100 ℃ of heating 3 hours.Remove pyridine under reduced pressure, the residue recrystallizing methanol gets 36 milligrams of 10-(3-(benzyloxycarbonyl amino)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.227～230 ℃ of fusing points; Mass spectrum m/z482(M +).
Example 30
10-(3-amino-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid.
10-(3-(benzyloxycarbonyl amino)-1-pyrrolidyl with gained in the example 29)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid (30 milligrams) is gone up hydrogenation 4.5 hours in 10 milligrams of 5%Pd/C in 2 milliliters of dimethyl formamides.Filter filtration catalizer, filtrate decompression concentrates, the residue recrystallizing methanol gets 16 milligrams of 10-(3-amino-1-pyrrolidyls)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.230～234 ℃ of fusing points (decomposition); Mass spectrum m/z 348(M +).
Following compounds can be by making with example 29 and 30 similar methods:
Figure 87106838_IMG55
Example 36
10-(3,4-dimethyl-1-piperazinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
9-fluoro-3-methyl isophthalic acid 0-(3-methyl isophthalic acid-piperazinyl with gained in the example 7)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the mixed solution that 4-Ben Bing oxadiazine-6-carboxylic acid (60 milligrams), 98% formic acid (1 milliliter) and 35% formaldehyde (1 milliliter) are formed stirs between 100～110 ℃.Heat after 2 hours, with the mixed solution reduction vaporization, residue is soluble in water, with 1N sodium hydroxide neutralization and use chloroform extraction.Extracting solution washes with water, uses anhydrous sodium sulfate drying again.After removing solvent under reduced pressure,, get 43 milligrams of 10-(3,4-dimethyl-1-piperazinyl with the crystalline residue recrystallizing methanol)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.257～259 ℃ of fusing points; Fast atom bombardment(FAB)-mass spectrum m/z 377(MH +).
Example 37
9-fluoro-10-(3-methoxyl group-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-carboxylic acid
The 9-fluoro-10-(3-hydroxyl-1-pyrrolidyl that in example 21, makes)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, add 30 milligrams of oil and 40 microlitre methyl iodide that contain 60% sodium hydride in the suspension of 4-benzodiazine-6-carboxylic acid (100 milligrams) and 10 milliliters of dry dimethyl formamides.After the stirring at room 2 hours, add 30 milligram of 60% sodium hydride and 40 microlitre methyl iodide again, mixed solution stirred 3 hours at 45 ℃, then, removed solvent under reduced pressure.In residue, add 2 milliliters of cold water and 2.3 milliliters of 0.5N sodium hydroxide, the suspension that obtains was heated 2 hours in 100 ℃.Then mixed solution is chilled to room temperature, with acetic acid neutralization, dilute with water again.The mixed solution chloroform extraction, the extracting solution that obtains washes with water, anhydrous sodium sulfate drying, then through concentrating under reduced pressure, gets a crystalline residue.This resistates separates with silica gel chromatography, makes eluent with acetone/chloroform (1: 9).Product gets 42 milligrams of 9-fluoro-10-(3-methoxyl group-1-pyrrolidyls through recrystallizing methanol)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.233～234 ℃ of fusing points; Fast atom bombardment(FAB)-mass spectrum m/z 364(MH +).
Example 38
9-fluoro-10-(4-methoxyl group-piperidino)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
9-fluoro-10-(4-methoxyl group-piperidino)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid can be with the 9-fluoro-10-(4-hydroxyl-piperidino that makes in the example 13)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-benzodiazine-6-carboxylic acid is through making with example 37 similar methods.With obtaining its crystallization behind chloroform/normal hexane recrystallization.229～233 ℃ of fusing points (decomposition); Mass spectrum m/z377(M +).
Example 39
10-(1,1-dioxide-4-thio-morpholinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-carboxylic acid
50 milligrams of 9-fluoro-3-methyl-7-oxo-10-(4-thio-morpholinyls that in example 11, make)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, add 74 milligrams of purity in the suspension that 4-benzene and oxadiazine-6-carboxylic acid and 5 milliliters of methylene dichloride form and be 70% between the chloro peroxybenzoic acid.Mixed solution stirred under room temperature 18 hours, pressure reducing and steaming solvent then, residue with the mixed solution washing of ether, methylene dichloride and chloroform and methyl alcohol, is used the dimethyl formamide recrystallization respectively, gets 22 milligrams of 10-(1,1-dioxide-4-thio-morpholinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.Fusing point＞300 ℃; Mass spectrum m/z 397(M +).
Example 40
9-fluoro-3-methyl-7-oxo-10-(4-(2-oxo-n-propyl)-1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
With 50 milligrams of 9-fluoro-3-methyl-7-oxo-10-(1-piperazinyls that make in the example 6)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the mixed solution of 4-benzodiazine-6-carboxylic acid, 17 microlitre acetone dichlorides, 40 microlitre triethylamines and 1 milliliter of dry dimethyl formamide composition boils off volatile constituent under the decompression then in 80 ℃ of heating 3.5 hours.Debris suspends in water.Filter collecting precipitation.With the mixed solvent recrystallization of methylene dichloride and methyl alcohol, get 32 milligrams of 9-fluoro-3-methyl-7-oxo-10-[4-(2-oxo-n-propyls)-the 1-piperazinyl]-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid.225～229 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 405(MH +).
According to making following compounds with example 40 similar methods:
Figure 87106838_IMG56
Example R 70The fast atom of fusing point ℃ recrystallization
Solvent bombardment mass spectrum M/z
41
Figure 87106838_IMG57
223～226(decomposes) dimethyl formamide 467(MH +)
42 CH 3CH 2-273～275(decomposes) EtOH 377(MH +)
43 CH 3CH 2CH 2-255～257(decomposes) EtOH 391(MH +)
44 FCH 2CH 2-257～259(decomposes) EtOH 395(MH +)
45 HO 2CCH 2-256～259(decomposes) H 2O 407(MH +)
46 CH 2=CHCH 2-236～238(decomposes) MeOH 389(MH +)
47
Figure 87106838_IMG58
275～276(decomposes) EtOH 484(MH +)
Example 48
10-[3-[(ethyl methylamino-) methyl]-the 1-pyrrolidyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-carboxylic acid
10-[3-[(ethyl methylamino-) methyl]-the 1-pyrrolidyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, but the methyl 9-fluoro-3-methyl isophthalic acid 0-[3-[(methylamino-that makes in 4-benzodiazine-6-carboxylic acid use-case 17)]-the 1-pyrrolidyl]-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid and iodoethane is by making with example 40 similar methods.Behind the mixed solvent recrystallization of chloroform, methyl alcohol and normal hexane, can get crystallization.210～225 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 405(MH +).
Example 49
10-(4-(3-carboxypropanoyl)-1-piperazinyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid.
With 50 milligrams of 9-fluoro-3-methyl-7-oxo-10-(1-piperazinyls that make in the example 6)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the mixture of 4-Ben Bing oxadiazine-6-carboxylic acid, 21.6 milligrams of succinyl oxides, 40 microlitre triethylamines and 4 milliliters of dry dimethyl formamide compositions was in 80 ℃ of heating 2 hours, and the pressure reducing and steaming solvent suspends in water residue then.Filter collecting precipitation,, get 50 milligrams of 10-(4-(3-carboxypropanoyl)-1-piperazinyl with the mixed solvent recrystallization of methylene dichloride and methyl alcohol)-9-fluoro-3-methyl-7-oxo-2; 3-dihydro-7H-pyrido (3,2,1-ij)-1; 3,4-Ben Bing oxadiazine-6-carboxylic acid.257～259 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 449(MH +).
Example 50
10-(4-ethanoyl-1-piperazinyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-carboxylic acid
10-(4-ethanoyl-1-piperazinyl)-9-fluoro-3-methyl-7-oxo-2; 3-dihydro-7H-pyrido [3,2,1-ij]-1; 3; 9-fluoro-3-methyl-7-oxo-10-(1-piperazinyl that 4-benzodiazine-6-carboxylic acid can make in example 6)-2,3-dihydro-7H-pyrido (3,2; 1-ij)-1; 3,4-Ben Bing oxadiazine-6-carboxylic acid and acetic anhydride is by making with the similar method of example 49.Behind the methylene chloride recrystallization, get its crystallization.294～296 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 391(MH +).
Example 51
9-fluoro-3-methyl-7-oxo-10-(4-(3-oxo normal-butyl)-1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
With 30 milligrams of 9-fluoro-3-methyl-7-oxo-10-(1-piperazinyls that make in the example 6)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the mixture of 4-Ben Bing oxadiazine-6-carboxylic acid, 36 microlitre methyl vinyl ketones and 1 milliliter of ethanol composition refluxed 12 hours, was chilled to room temperature then.Filter to collect the precipitation of separating out, with alcohol crystal it, 28 milligrams of 9-fluoro-3-methyl-7-oxo-10-(4-(3-oxo-normal-butyl)-1-piperazinyls)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.187～189 ℃ of (decomposition) fast atom bombardment(FAB)s of fusing point-mass spectrum m/z 419(MH +).
Example 52
9-fluoro-3-methyl-7-oxo-10-[4-(sulfonic acid (Sulfonato) methyl)-and the 1-piperazinyl]-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid disodium salt
The mixed solution that 26 milligram of 35% formalin, 32 milligrams of sodium bisulfites and 0.5 ml water are formed is chilled to room temperature then in 75 ℃ of heating 30 minutes.In this solution, add the 9-fluoro-3-methyl-7-oxo-10-(1-piperazinyl that makes in the example 6)-2,3-dihydro-7H-pyrido-[3,2,1-ij]-1,3,4-benzo aldehyde diazine-6-carboxylic acid (100 milligrams) and sodium hydroxide (15 milligrams).Mixture after 1 hour, adds 2 milliliters of ethanol in 75 ℃ of heating, then mixture is chilled to room temperature.Filter and collect the precipitation of separating out.Water/ethanol (1: 2) recrystallization.Get 9-fluoro-3-methyl-7-oxo-10-(4-(sulfonic acid methyl)-1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid disodium salt.260～263 ℃ of fusing points (decomposition); H-nuclear magnetic resonance spectrum (D 2O) δ: 2.98(3H, S), 3.05(4H, m), 3.39(4H, m), 3.84(2H, S), 5.18(2H, S), 7.55(1H, d, J=13.4Hz), 8.34(1H, S).
Example 53
10-(4-(4-aminobenzyl)-1-piperazinyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
The 9-fluoro-3-methyl isophthalic acid 0-[4-(4-nitrobenzyl that makes in the example 47)-the 1-piperazinyl]-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid (100 milligrams) is gone up hydrogenation 2 hours in 10 milligrams of 5%Pd/c in methylene chloride (1: 1).After removing by filter catalyzer, filtrate under reduced pressure is concentrated into dried, the residue ethyl alcohol recrystallization, get 69 milligrams of 10-[4-(4-aminobenzyls)-the 1-piperazinyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid.237～238 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z454(MH +).
Example 54
The 10-[3-(amino methyl)-the 1-pyrrolidyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
With 10-(3-(acetylamino the methyl)-1-pyrrolidyl that makes in the example 19)-9-fluoro-3-methyl-7-oxo-2; 3-dihydro-7H-pyrido (3; 2; 1-ij)-1; 3; the mixture that 4-Ben Bing oxadiazine-6-carboxylic acid (40 milligrams) and 1N sodium hydroxide (2.5 milliliters) are formed is in 100 ℃ of heating 3 hours, be chilled to room temperature after, reaction mixture neutralizes with acetic acid.Filter and collect the precipitation of separating out, use recrystallizing methanol, get 15 milligrams of 10-(3-(amino methyl)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.177～180 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 363(MH +).
Example 55
6-fluoro-8-hydroxyl-7-(1-imidazolyl)-the 1-(methylamino-)-4-oxo-1,4-dihydro-3-quinoline carboxylic acid's preparation
With fmoc-2 imidazole (32 milligrams) join make among the reference example i that is stirring 6,7-two fluoro-8-hydroxyl-1-(methylamino-s)-4-oxo-1, in dry dimethyl formamide (2 milliliters) solution of 4-dihydro-3-quinoline carboxylic acid (50 milligrams).Continue to stir under the room temperature 2 hours, then in 80 ℃ of restir 5 hours.The pressure reducing and steaming solvent suspends in water resistates, with vinegar acid for adjusting pH value to 5.The precipitation that filtration is separated out is washed precipitation with methyl alcohol, gets 35 milligrams of 6-fluoro-8-hydroxyl-7-(1-imidazolyl)-the 1-(methylamino-)-4-oxo-1,4-dihydro-3-quinoline carboxylic acid's buff powder.Fast atom bombardment(FAB)-mass spectrum m/z319(MH +); H-nuclear magnetic resonance spectrum (d 6-DMSO) δ: 2.82(3H, S), 7.10(1H, d, J=10.7Hz), 7.61(1H, d), 7.75(1H, d), 8.62(1H, S), 8.92(1H, S), 15.33(1H, br.S).
Example 56
9-fluoro-10-(1-imidazolyl)-and 3-methyl-7-oxo-2.3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
With the 6-fluoro-8-hydroxyl-7-(1-imidazolyl that makes in the example 55)-the 1-(methylamino-)-4-oxo-1,4-dihydro-3-quinoline carboxylic acid (15 milligrams) 35% formalin (1 milliliter of) He the suspension in diox (1 milliliter) mixed solvent under nitrogen atmosphere in 100～110 ℃ of heating 1.5 hours.The pressure reducing and steaming solvent, the crystalline residue methanol wash gets 15 milligrams of 9-fluoro-10-(1-imidazolyl)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the baby pink powder of 4-Ben Bing oxadiazine-6-carboxylic acid.Through dimethyl formamide and ether recrystallization, can make analytic sample.Fusing point＞300 ℃; Fast atom bombardment(FAB)-mass spectrum m/z331(MH +).
9-fluoro-10-(1-imidazolyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid is also available 9,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-benzodiazine-6-carboxylic acid and imidazoles make by the method that is similar to example 5 in dimethyl sulfoxide (DMSO).
Example 57
9-fluoro-10-(3-hydroxyl-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-benzyl carboxylate
With the 9-fluoro-10-(3-hydroxyl-1-pyrrolidyl that makes in the example 21)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the mixed solution that 4-Ben Bing oxadiazine-6-carboxylic acid (10 milligrams), Anhydrous potassium carbonate (8 milligrams) and dimethyl formamide (0.5 milliliter) are formed adds 10.8 milligrams of bromotoluenes then in stirring at room 1.5 hours.Mixture is in stirring at room 3 hours, decompression evaporation down then.
Residue is suspended in water, use chloroform extraction.Be concentrated into dried under the extracting solution decompression.Residue grinds with ether, gets 11 milligrams of 9-fluoro-10-(3-hydroxyl-1-pyrrolidyls)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-benzyl carboxylate.196～198 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 440(MH +).
Example 58
10-(3-chloro-1-pyrrole pyrrole alkyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-benzyl carboxylate
With the 9-fluoro-10-(3-hydroxyl-1-pyrrolidyl that makes in the example 57)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-benzyl carboxylate (8 milligrams) is dissolved in 0.2 milliliter of thionyl chloride, and in 60 ℃ of stirrings 15 minutes, the reaction mixture dilute with water was also used chloroform extraction.
Extracting solution concentrates down in decompression, residue is analyzed at the enterprising circumstances in which people get things ready for a trip spectrometry of silica gel (2 gram), use the chloroform wash-out, obtain 2.8 milligrams of 10-(3-chloro-1-pyrrolidyls)-9-fluoro-3-methyl-7-oxo-2,3 ,-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-benzyl carboxylate.Fusing point＞300 ℃; Fast atom bombardment(FAB)-mass spectrum m/z458(MH +), 460(MH+2) +
Example 59
10-(3-chloro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
2.5 milligrams of 10-(3-chloro-1-pyrrolidyls that make in the example 58)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-benzyl carboxylate hydrogenation in chloroform on 1 milligram of 5%Pd/c.
After removing by filter catalyzer, filtrate under reduced pressure is concentrated into dried.The residue ethyl alcohol recrystallization gets 1.0 milligrams of 10-(3-chloro-1-pyrrolidyls)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.269～272 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 368(MH +), 370(MH+2) +
Example 60
Through intermediate fluoro borane, preparation 9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid
(a) with make in the example 19,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the mixture of 4-benzene and oxadiazine-6-carboxylic acid (100 milligrams) and 1 milliliter of 60% fluoroboric acid water liquid was in 90 ℃ of heating 12 hours.After reaction mixture is chilled to room temperature, filter and collect the precipitation of separating out, wash with methyl alcohol, drying under reduced pressure gets 110 milligrams thick 9 then, 10-two fluoro-6-(((two fluoro boryl) oxygen) carbonyl)-3-methyl-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-7-ketone; Fast atom bombardment(FAB)-mass spectrum m/z 331(MH +).
(b) 15 microlitre N methyl piperazines and 20 microlitre triethylamines are joined in dimethyl sulfoxide (DMSO) (1 milliliter) solution of the above-mentioned borane intermediate (33 milligrams) that is stirring.After the stirring at room 3 hours, with the reaction mixture lyophilize.The residue methanol crystallization gets 28 milligrams of 6-(((two fluoro boryl) oxygen) carbonyl)-9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the yellow crystal of 4-benzene and oxadiazine-7-ketone.228～230 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 411(MH +).
(c) 3 microlitre triethylamines are joined in 95% ethanol (1 milliliter) solution of above-mentioned borine intermediate (5 milligrams).Behind the reflux 4 hours, reaction mixture is chilled to room temperature.Filter and collect the precipitation of separating out, get 9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.268～269 ℃ of fusing points (decomposition).
Example 61
Through acetoxyl group borane intermediate preparation 9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid
(a) with make in the example 19,10-two fluoro-3-methyl-7-oxos-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the mixed solution that 4-Ben Bing oxadiazine-6-carboxylic acid (100 milligrams), acetic anhydride (1 milliliter) and triacetyl oxygen base borane (100 milligrams) are formed was in 140 ℃ of heating 15 minutes.With reaction mixture decompression evaporation down.Residue grinds with acetone, filters then, gets 138 milligrams of 6-(((diacetoxy boryl) oxygen base) carbonyl)-9,10-two fluoro-3-methyl-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-benzene and oxadiazine-7-ketone.Fast atom bombardment(FAB)-mass spectrum m/z411(MH +).
(b) 15 microlitre N methyl piperazines and 20 microlitre triethylamines are joined in methyl-sulphoxide (1 milliliter) solution of above-mentioned borane intermediate (41 milligrams).Mixture is in stirring at room after 2 hours, with the reaction mixture lyophilize.Residue methanol recrystallization gets 34 milligrams of 6-(((diacetoxy boron (alkane) base) oxygen base) carbonyl)-9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the yellow crystal of 4-Ben Bing oxadiazine-7-ketone; 156～157 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 491(MH +).
(c) above-mentioned borane intermediate (5 milligrams) is suspended in 0.1 milliliter of acetone, adds 2.5 microlitre concentrated hydrochloric acids.Reaction mixture stirred under room temperature 30 minutes, cooled off in the ice bath then.Filter and collect the precipitation of separating out.Precipitation is dissolved in 0.1 milliliter of 95% ethanol, adds 2 microlitre triethylamines in this solution, this mixture 1 hour then refluxes.After solution is chilled to room temperature, filter and collect the precipitation of separating out, get 9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.268～269 ℃ of fusing points (decomposition).
Example 62
10-(3-(benzyloxycarbonyl amino)-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid new pentane acyloxy methyl esters.
With 10-(3-(benzyloxycarbonyl the amino)-1-pyrrolidyl that makes in the example 29)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the mixed solution that 4-Ben Bing oxadiazine-6-carboxylic acid (290 milligrams), oxy acid methyl neopentyl chlorine (130 microlitre), Anhydrous potassium carbonate (166 milligrams) and dry dimethyl formamide (10 milliliters) are formed stirred 8 hours in 45 ℃.Pressure reducing and steaming solvent then, residue is dissolved in the methylene dichloride.This dichloromethane solution is washed with water, use anhydrous sodium sulfate drying then.Decompression is evaporating solvent down, and the residue re-crystallizing in ethyl acetate gets 325 milligrams of 10-(3-(benzyloxycarbonyl amino)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid new pentane acyloxy methyl esters.185～188 ℃ of fusing points; Fast atom bombardment(FAB)-mass spectrum m/z597(MH +).
Example 63
10-(3-amino-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid new pentane acyloxy methyl esters.
10-(3-amino-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, but 10-(3-(benzyloxycarbonyl the amino)-1-pyrrolidyl that makes in 4-benzene and oxadiazine-6-carboxylic acid new pentane acyloxy methyl esters use-case 62)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid new pentane acyloxy methyl esters (200 milligrams) is by making with example 30 similar methods.After from the mixing solutions of ethyl acetate and normal hexane, separating out, get a light brown powder: H-nuclear magnetic resonance spectrum (CDCL 3) δ: 1.22(9H, S), 1.6-2.4(2H, m), 2.99(3H, s), 3.3-4.0(5H, m), 4.98(2H, S), 5.96(2H, S), and 7.64(1H, d, J=14.4Hz), 8.37(1H, s); Fast atom bombardment(FAB)-mass spectrum m/z463(MH +).
Example 64
10-(3-(benzyloxycarbonyl amino)-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid, ethyl ester.
With 10-(3-(benzyloxycarbonyl the amino)-1-pyrrolidyl that makes in the example 29)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the mixed solution that 4-Ben Bing oxadiazine-6-carboxylic acid (337 milligrams), iodoethane (84 microlitre), Anhydrous potassium carbonate (193 milligrams) and dry dimethyl formamide (12 milliliters) are formed stirred 6 hours in 45 ℃.The pressure reducing and steaming solvent, residue is dissolved in the methylene dichloride.This dichloromethane solution washes with water.Use anhydrous sodium sulfate drying, decompression concentrates down then.The residue silicagel column of packing into, mixed solvent wash-out with chloroform/acetone (20: 1), pure component is merged, and under reduced pressure be concentrated into dried, the residue re-crystallizing in ethyl acetate, get 271 milligrams of 10-(3-(benzyloxycarbonyl amino)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, ethyl ester.204～207 ℃ of fusing points; Fast atom bombardment(FAB)-mass spectrum m/z 511(MH +).
Example 65
10-(3-amino-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid, ethyl ester
With 10-(3-(benzyloxycarbonyl the amino)-1-pyrrolidyl that makes in the example 64)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, ethyl ester (200 milligrams) is at 5% pd/c(120 milligram) on, hydrogenation is 23 hours in the mixed solvent of chloroform (25 milliliters) and methyl alcohol (10 milliliters).After removing by filter catalyzer, concentrate under the filtrate decompression, the silicagel column of then residue being packed into, the mixed solvent wash-out with chloroform and methyl alcohol (4: 1) merges pure component, and under reduced pressure is concentrated into dried.Residue is with preparing thin-layer chromatography (silica gel; CHCl 3/ MeOH, 3: 1) be further purified, use ethyl alcohol recrystallization, get 71 milligrams of 10-(3-amino-1-pyrrolidyls)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, ethyl ester.Fusing point 187-192 ℃ (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z377(MH +).
Example 66
10-(3-amino-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylate salt acidulants.
With the 10-(3-amino-1-pyrrolidyl that makes in the example 30)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the pH value of water (1 milliliter) solution of 4-Ben Bing oxadiazine-6-carboxylic acid (20 milligrams) transfers to 1.0 with 6N-HCI, then with this clear soln freeze-drying.Residue water/ethanol (1: 2) crystallization gets 19 milligrams of 10-(3-amino-1-pyrrolidyls)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylate salt acidulants.Fusing point 226-228 ℃ (decomposition).
Example 67
9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-and 7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-carboxylate salt acidulants.
9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-and 7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the hydrochloride of 4-benzodiazine-6-carboxylic acid can be according to making with the similar method of example 66.Fusing point 264-266 ℃ (decomposition).
Example 68
9-fluoro-3-methyl isophthalic acid 0-morpholino-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid sodium salt
With the 9-fluoro-3-methyl isophthalic acid 0-morpholino-7-oxo-2 that makes in the example 9,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid (14 milligrams) is suspended in 0.4 ml water, under agitation add 40 microlitre 1N sodium hydroxide, with this clear soln lyophilize, residue water/ethanol (1: 4) crystallization, get 12 milligrams of 9-fluoro-3-methyl isophthalic acid 0-morpholino-7-oxos-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid sodium salt.Fusing point＞300 ℃.
Example 69
9-fluoro-3-(2-fluoro ethyl)-10-(4-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
9-fluoro-3-(2-fluoro ethyl)-10-(4-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the 8-benzyloxy-6 that makes among 4-benzodiazine-6-carboxylic acid available reference example f, 7-two fluoro-1-(formamido groups)-4-oxo-1,4-dihydro-3-quinoline carboxylic acid ethyl ester, according to the operation of a series of reference examples (g, h and i) (replacing methyl iodide) and example 1 and example 5 with 1-bromo-2-fluoroethane, again after recrystallizing methanol, make its crystallization, 220～224 ℃ of fusing points; Mass spectrum m/z394(M +).
Example 70～77
The compound beginning that from example 1, makes, use and example 5 or example 29/30 described similar method, can make following compounds:
Figure 87106838_IMG59
Figure 87106838_IMG60
The compound that makes from example 1 begins, according to the similar method of example 5 or example 29/30, also can make following compounds: 10-(3-(aminomethyl)-4-methyl isophthalic acid-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid
10-(3-((ethylamino) methyl)-4-methyl isophthalic acid-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(aminomethyl)-4-chloro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(aminomethyl)-4-fluoro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-chloro-4-((methylamino-) methyl)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-fluoro-4-((methylamino-) methyl)-1-pyrrolidyl)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-chloro-4-((ethylamino) methyl)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-((ethylamino) methyl)-4-fluoro-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-methoxyl group-4-(methylamino-)-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(ethylamino)-4-methoxyl group-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-hydroxyl-4-methoxyl group-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-amino-4-chloro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-amino-4-fluoro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-[3-chloro-4-(methylamino-)-the 1-pyrrolidyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid,
9-fluoro-10-[3-fluoro-4-(methylamino-)-the 1-pyrrolidyl]-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid,
9-fluoro-3-methyl isophthalic acid 0-(1-oxidation-4-sulfo-sign indicating number quinoline base)-and 7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid,
9-fluoro-10-(3-hydroxyl-4-(methylamino-)-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid.
Example 78
10-(3-((4-ammonia benzyl) amino)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid
10-(3-((4-aminobenzyl) amino)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid can be according to the method that is similar to described in example 47 and 53, the 10-(3-that makes from example 30 amino-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carbonyl acid at first makes.Fusing point 180-182 ℃ (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z453(MH +).
Example 79
9-fluoro-10-[3-[[(dimethylamino) methylene radical]-amino]-the 1-pyrrolidyl]-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, the preparation of 4-benzodiazine-6-carboxylic acid
With the 10-(3-amino-1-pyrrolidyl that makes in the example 30)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-benzodiazine-6-carboxylic acid (14 milligrams) and N, dinethylformamide methylal (6 microlitre) have the suspension that forms in 0.5 milliliter of dry dimethyl formamide to stir under room temperature 8.5 hours.Filter collecting precipitation, respectively with dimethyl formamide and ether washing, use the dimethyl formamide recrystallization again, get 8 milligrams of 9-fluoro-10-[3-[[(dimethylaminos) methylene radical) amino)-the 1-pyrrolidyl)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the light yellow crystallization of 4-Ben Bing oxadiazine-6-carboxylic acid.218～220 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 404(MH +).
Example 80
9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-and 7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3, the preparation of 4-Ben Bing oxadiazine-6-carboxylic acid sodium salt
With 520 milligrams of 9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyls)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid is dissolved in 2.88 milliliters of 0.5N sodium hydroxide solutions.This clear soln is evaporated down in decompression, get 555 milligrams of buff powders, use ethyl alcohol recrystallization, in 80 ℃ of vacuum-dryings two days, get 475 milligrams of 9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyls)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid sodium.252～254 ℃ of fusing points (decomposition); Fast atom bombardment(FAB)-mass spectrum m/z 385.
Following example has illustrated the pharmaceutical preparation that contains compound provided by the present invention:
Example A
Preparation respectively contains the locking gelatine capsule of following component according to a conventional method:
9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-and 7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-
200 milligrams of benzodiazines-6-carboxylic acid
Luviskol(water-soluble polyethylene base pyrrolidone) 20 milligram
20 milligrams of mannitols
15 milligrams in talcum
2 milligrams of Magnesium Stearates
257 milligrams
Example B
Preparation respectively contains the tablet of following component according to a conventional method
9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-
Oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-
200 milligrams of Ben Bing oxadiazines-6-carboxylic acid
44 milligrams of starch
30 milligrams of calcium carboxymethylcelluloses
40 milligrams of crystalline celluloses
6 milligrams of Magnesium Stearates
320 milligrams

Claims (14)

1, the 10-with therapeutic activity of preparation formula I replaces-9-fluoro-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3, but the salt of 4-Ben Bing oxadiazine-6-carboxylic acid derivative and hyoscine thereof and the hydrate of formula I compound or their salt or the similarity method of solvate
Figure 87106838_IMG2
Wherein, R 1Be hydrogen atom or the carboxylic acid protecting group who is selected from low alkyl group, benzyl and low-grade alkane acidyl oxyalkyl; R 2It is the low alkyl group that can be replaced by fluorine atom; R 3Be the hydrogen atom or the low alkyl group that can be replaced by hydroxyl or two-low-grade alkyl amino, R 5Be low alkyl group and R 6Be two-low-grade alkyl amino-low alkyl group, perhaps R 5And R 6Nitrogen-atoms adjacent thereto forms together
-one piperazine ring, this ring can be replaced by low alkyl group, oxygen base and/or phenyl C-, and/or by low alkyl group, sulfonation low alkyl group, nitrobenzyl, ammonia benzyl, hydroxy lower alkyl, halogen-low alkyl group, carboxyl-low alkyl group, low-grade alkenyl and/or replaced by the basic N-shown in the following formula
(n=0-2 in this formula, R 8Be the phenyl or the low alkyl group that can be replaced by carboxyl or phenyl);
-morpholino the ring that can be replaced by low alkyl group;
-thiomorpholine ring or 1,1-titanium dioxide-thiomorpholine ring;
-pyrrolidine ring, this ring can be replaced by the base of amino, lower alkyl amino, lower alkoxy, amino-low alkyl group, low alkyl group, hydroxyl, halogen, benzyloxy carbonyl amino, low alkyl group-piperazinyl, phenyl, lower alkyl amino-low alkyl group, amino benzyl amino and/or following formula
Figure 87106838_IMG3
R wherein 50And R 51It is low alkyl group;
-the imidazole ring that can be replaced by low alkyl group;
-piperidine ring, this ring can be replaced by amino-low alkyl group, hydroxyl, pyrryl, amino, low alkyl group-amino and/or lower alkoxy; Or
-six hydrogen-1, the 4-diaza
Figure 87106838_IMG4
Ring;
This method comprises
(a) will lead to the compound of formula III representative and the amine reaction of logical formula IV representative,
Figure 87106838_IMG5
(Ⅲ)
In the formula III, R 1, R 2And R 3Definition as hereinbefore, X ' is a halogen atom; Wherein the amino of Cun Zaiing, hydroxyl and/or carboxyl can be protected,
Figure 87106838_IMG6
(Ⅳ)
In the formula IV, R 5And R 6As defined above,
Subsequently, if desired, again protecting group is removed, perhaps
(b) compound and the general formula with general formula (V) representative is R 3The aldehyde compound of-CHO (VI), or its polymkeric substance, acetal or enol ether reaction,
Figure 87106838_IMG7
(Ⅴ)
In the formula (V), R 1, R 2, R 5And R 6With the R in the formula VI 3Definition as hereinbefore; Wherein the amino of Cun Zaiing, hydroxyl and/or carboxyl can be protected,
Then, if necessary, again protecting group is removed, perhaps
(c) be R in the preparation formula I 5R 6N-is the compound of the piperazine ring of an aforesaid N-replacement, can be with R in the formula I 5R 6N-is the compound of a unsubstituted piperazinyl of N-,
(c1) be R with general formula 70The compound reaction of-Y (X), Y is a leavings group in the formula (X), R 70Be-(CH 2) nCOR 8, low alkyl group, nitrobenzyl, hydroxyl low-grade alkyl, fontanel be for low alkyl group or low-grade alkenyl, or
(c2) be R with general formula 9-CO-CH=CH 2The Michael receptor reaction of (XI), R in the formula (XI) 9Be low alkyl group, or
(c3) with formaldehyde and formic acid or a kind of basic metal bisulfite reaction, or
(c4) compound with general formula (XII) reacts:
Figure 87106838_IMG8
(Ⅻ)
Z is C in the formula (XII) 2-C 3-alkylidene group; Or
(d) be R in the preparation formula I 5R 6N-is 1, and 1-dioxy-thiomorpholine can be with R for the compound of base 5R 6N-is the respective compound oxidation of thiomorpholine for base; Or
(e) be R in the preparation formula I 5R 6N-is amino or the tetramethyleneimine of aminomethyl replacement or the compound of piperidine ring, can carry out shortening by benzyloxy carbonyl amino compound or benzyloxy carbonyl aminomethylation compound, makes the respective compound with amino or aminomethyl protecting group slough protecting group; Or
(f) be R in the preparation formula I 5R 6N-is the compound of halogenated pyrrole alkane ring, can be by R in halogenation and the formula I 1Be the corresponding hydroxyl pyrrolidine compound of compound of aforesaid carboxyl-protecting group, if desired, slough described protecting group R 1Or
(g) be R in the preparation formula I 5R 6N-is the compound of ammonia benzyl diethylenediamine ring, the nitrobenzyl diethylenediamine compound shortening of corresponding formula I can be made nitroreduction wherein; Or
(h) for preparing the compound of following formula
Ⅰa
R wherein 1-R 3Definition suc as formula shown in the I, R 50And R 51Be low alkyl group,
Can be with the amino and the N of the aminopyrrolidine compounds of corresponding formula I, the reaction of N-(two low alkyl groups) methane amide methylal; Or
(i) be R in the preparation formula I 1Be the compound of carboxyl-protecting group, can make the carboxylic acid of formula I carry out corresponding esterification, or
(j) but for salt, hydrate or the solvate of the hyoscine of preparation or the hydrate or the solvate of this salt, change the compound of formula I into a kind of salt, hydrate or solvate or change the hydrate or the solvate of this salt.
2,, it is characterized in that according to (a)-(h), (i) and the method one of (j) is reacted according to the method for claim 1.
3, according to the preparation method of the compound of claim 1, this compound is 9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the hydrate of the perhaps salt of its hyoscine, or this compound or pharmaceutically acceptable salt thereof or solvate is characterized in that using the starting raw material of corresponding replacement.
4, according to the preparation method of the compound of claim 1, this compound is 9-fluoro-3-methyl-7-oxo-10-(1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the hydrate of the perhaps salt of its hyoscine, or this compound or pharmaceutically acceptable salt thereof or solvate is characterized in that using the starting raw material of corresponding replacement.
5, according to the preparation method of the compound of claim 1, this compound is 9-fluoro-3-methyl isophthalic acid 0-(3-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the hydrate of the perhaps salt of its hyoscine, or this compound or pharmaceutically acceptable salt thereof or solvate is characterized in that using the starting raw material of corresponding replacement.
6, according to the preparation method of the compound of claim 1, this compound is 9-fluoro-3-methyl-7-oxo-10-(3-phenyl-peiperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the hydrate of the perhaps salt of its hyoscine, or this compound or pharmaceutically acceptable salt thereof or solvate the method is characterized in that the starting raw material of having used corresponding replacement.
7, according to the preparation method of the compound of claim 1, this compound is 9-fluoro-3-methyl isophthalic acid 0-morpholino-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the hydrate of the perhaps salt of its hyoscine, or this compound or pharmaceutically acceptable salt thereof or solvate is characterized in that having used corresponding starting raw material.
8, according to the preparation method of the compound of claim 1, this compound is: 10-(3-((ethylamino) methyl)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the perhaps salt of its hyoscine, the perhaps hydrate of this compound or pharmaceutically acceptable salt thereof or solvate is characterized in that using the starting raw material of corresponding replacement.
9, according to the preparation method of the compound of claim 1, this compound is: 10-(3-amino-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the perhaps salt of its hyoscine, the perhaps hydrate of this compound or pharmaceutically acceptable salt thereof or solvate is characterized in that using the starting raw material of corresponding replacement.
10, according to the preparation method of the compound of claim 1, this compound is 9-fluoro-3-methyl isophthalic acid 0-(3-(methylamino-)-1-pyrrolidyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the perhaps salt of its hyoscine, the perhaps hydrate of this compound or pharmaceutically acceptable salt thereof or solvate is characterized in that using the starting raw material of corresponding replacement.
11, according to the preparation method of the compound of claim 1, this compound is 10-(4-(4-ammonia benzyl)-1-piperazinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the perhaps salt of the hyoscine of this compound, the perhaps hydrate of this compound or pharmaceutically acceptable salt thereof or solvate is characterized in that using the starting raw material of corresponding replacement.
12, according to the preparation method of the compound of claim 1, this compound be 10-(trans-3-amino-4-methyl isophthalic acid-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the perhaps salt of its hyoscine, the perhaps hydrate of this compound or pharmaceutically acceptable salt thereof or solvate is characterized in that using the starting raw material of corresponding replacement.
13, according to the preparation method of the compound of claim 1, this compound be 10-(trans-3-amino-4-methoxyl group-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but the perhaps salt of its hyoscine, the perhaps hydrate of this compound or pharmaceutically acceptable salt thereof or solvate is characterized in that using the starting raw material of corresponding replacement.
14, according to the preparation method of the compound of claim 1, this compound is selected from following compounds:
9-fluoro-3-methyl isophthalic acid 0-(3-((methylamino-)-methyl))-1-pyrrolidyl)-and 7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(ethylamino)-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3,4-dimethyl-1-piperazinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-methoxyl group-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl-7-oxo-10-(4-(3-oxo-normal-butyl)-1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl-7-oxo-10-(4-(sulphonate methyl (Sulfonatomethyl))-and the 1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(aminomethyl)-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(1-imidazolyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(4-ethyl-1-piperazinyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(4-(2-hydroxyethyl)-1-piperazinyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-imidazolyl)-and 7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl isophthalic acid 0-(3-methyl-4-((methylamino-) methyl)-1-pyrrolidyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(aminomethyl)-4-methyl isophthalic acid-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(ethylamino) methyl-4-methyl isophthalic acid-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(aminomethyl)-4-chloro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(aminomethyl)-4-fluoro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-chloro-4-(methylamino-) methyl isophthalic acid-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-fluoro-4-((methylamino-) methyl)-1-pyrrolidyl)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-chloro-4-((ethylamino) methyl)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-((ethylamino) methyl)-4-fluoro-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-amino-4-methoxyl group-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-methoxyl group-4-(methylamino-)-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij) 1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(ethylamino)-4-methoxyl group-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-hydroxyl-4-methoxyl group-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-amino-4-chloro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-amino-4-fluoro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-chloro-4-(methylamino-)-the 1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-fluoro-4-(methylamino-)-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(4-(aminomethyl)-piperidino)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(4-hydroxyl-piperidino)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl-7-oxo-10-(4-(1-pyrryl)-piperidino)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(1-high-carbon piperazinyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-hydroxyl-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3, dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl-7-oxo-10-(4-n-propyl-1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(4-(2-fluoro ethyl)-1-piperazinyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(4-carboxymethyl)-1-piperazinyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(4-allyl group-1-piperazinyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(1,1-dioxide-4-thio-morpholinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl isophthalic acid 0-(1-oxide compound-4-thio-morpholinyl)-and 7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl-7-oxo-10-(4-(2-oxo-n-propyl)-1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-chloro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-(2-fluoro ethyl)-10-(4-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(4-amino-piperidino)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl isophthalic acid 0-(4-(methylamino-)-piperidino)-and 7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(4-(ethylamino)-piperidino)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-((ethylmethylamino) methyl)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-amino-4-hydroxy-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-hydroxyl-4-(methylamino-)-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl-7-oxo-10-(4-thio-morpholinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(2,6-dimethyl-4-morpholinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(kharophen)-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(2-(dimethylamino) ethyl) methylamino-}-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl-7-oxo-10-(3-oxo-1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-2-(methylol)-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
2-((dimethylamino) methyl)-9-fluoro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-and 7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(benzyloxycarbonyl amino)-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl-7-oxo-10-(4-phenacyl-1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl isophthalic acid 0-(4-(4-nitrobenzyl)-1-piperazinyl)-and 7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(4-(3-carboxypropanoyl)-1-piperazinyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxyl,
10-(4-ethanoyl-1-piperazinyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(4-methoxyl group-piperidino)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-2,3-dimethyl-10-(1-methyl isophthalic acid-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-2,3-dimethyl-7-oxo-10-(1-piperazinyl)-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-(benzyloxycarbonyl amino)-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, ethyl ester,
10-(3-amino-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, ethyl ester,
9-fluoro-10-(3-hydroxyl-1-pyrrolidyl)-and 3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-benzyl carboxylate,
10-(3-chloro-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-benzyl carboxylate,
10-(3-(benzyloxycarbonyl amino)-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid pivalyl oxygen methyl esters,
10-(3-amino-1-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid pivalyl oxygen methyl esters,
10-(3-((4-ammonia benzyl) amino)-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [3,2,1-ij]-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-10-(3-(((dimethylamino) methylene radical) amino)-1-pyrrolidyl)-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl isophthalic acid 0-(3-(4-methyl isophthalic acid-piperazinyl)-1-pyrrolidyl)-and 7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(3-amino-3-methyl isophthalic acid-pyrrolidyl)-and 9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(is trans-3-amino-4-phenyl-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl isophthalic acid 0-(3-methyl-3-((methylamino-) methyl)-1-pyrrolidyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
9-fluoro-3-methyl isophthalic acid 0-(trans-3-((methylamino-) methyl)-4-phenyl-1-pyrrolidyl)-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid,
10-(is trans-3-amino-4-hydroxy-1-pyrrolidyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido (3,2,1-ij)-1,3,4-Ben Bing oxadiazine-6-carboxylic acid, but or the salt of their hyoscine, the hydrate of these compounds or their pharmaceutical salts or solvate is characterized in that using the starting raw material of corresponding replacement.
CN87106838A 1986-09-12 1987-09-12 Tricyclic compounds Expired CN1017800B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP86112619 1986-09-12
EP86112619.1 1986-09-12

Publications (2)

Publication Number Publication Date
CN87106838A CN87106838A (en) 1988-05-11
CN1017800B true CN1017800B (en) 1992-08-12

Family

ID=8195410

Family Applications (1)

Application Number Title Priority Date Filing Date
CN87106838A Expired CN1017800B (en) 1986-09-12 1987-09-12 Tricyclic compounds

Country Status (22)

Country Link
JP (3) JPH0696578B2 (en)
KR (1) KR960002857B1 (en)
CN (1) CN1017800B (en)
AT (1) AT389119B (en)
AU (1) AU602534B2 (en)
CA (1) CA1336905C (en)
CZ (1) CZ281195B6 (en)
DK (1) DK173330B1 (en)
DZ (1) DZ1124A1 (en)
FI (1) FI86428C (en)
HU (1) HU199481B (en)
IE (1) IE61624B1 (en)
IL (1) IL83814A (en)
MC (1) MC1850A1 (en)
MX (1) MX8302A (en)
NO (1) NO169125C (en)
NZ (1) NZ221681A (en)
PH (1) PH23930A (en)
PT (1) PT85686B (en)
SK (1) SK660487A3 (en)
ZA (1) ZA876636B (en)
ZW (1) ZW16387A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW16387A1 (en) * 1986-09-12 1988-05-25 Hoffmann La Roche Tricyclic compounds
JP4820290B2 (en) * 2004-05-13 2011-11-24 第一三共株式会社 Substituted pyrrolidine derivatives
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
AU2007225088B2 (en) 2006-03-13 2012-09-13 Kyorin Pharmaceutical Co., Ltd Aminoquinolones as GSK-3 inhibitors
CN101855228B (en) 2007-09-11 2012-10-24 杏林制药株式会社 Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
CA2699152C (en) 2007-09-12 2015-11-24 Activx Biosciences, Inc. Spirocyclic aminoquinolones as gsk-3 inhibitors
FR2928150A1 (en) * 2008-02-29 2009-09-04 Vetoquinol Sa Sa NOVEL 7-SUBSTITUTED 3-CARBOXY-OXADIAZINO-QUINOLONES DERIVATIVES, THEIR PREPARATION AND APPLICATION AS ANTI-BACTERIANS
EP2145891A1 (en) * 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
EP2406266B1 (en) 2009-03-11 2013-12-25 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
CN107522718B (en) * 2017-09-14 2019-11-08 浙江国邦药业有限公司 A kind of synthetic method of Marbofloxacin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW16387A1 (en) * 1986-09-12 1988-05-25 Hoffmann La Roche Tricyclic compounds

Also Published As

Publication number Publication date
NO873816L (en) 1988-03-14
PT85686A (en) 1987-10-01
IE61624B1 (en) 1994-11-16
CA1336905C (en) 1995-09-05
JPH0819120B2 (en) 1996-02-28
PH23930A (en) 1990-01-23
FI86428C (en) 1992-08-25
AT389119B (en) 1989-10-25
DK173330B1 (en) 2000-07-24
HUT47294A (en) 1989-02-28
JPH0696578B2 (en) 1994-11-30
KR960002857B1 (en) 1996-02-27
JPS63132891A (en) 1988-06-04
KR880003954A (en) 1988-06-01
DK477287D0 (en) 1987-09-11
MC1850A1 (en) 1988-09-30
AU7811487A (en) 1988-03-17
NO873816D0 (en) 1987-09-11
ZW16387A1 (en) 1988-05-25
ATA263887A (en) 1989-03-15
NZ221681A (en) 1990-12-21
AU602534B2 (en) 1990-10-18
SK278990B6 (en) 1998-05-06
FI873940A0 (en) 1987-09-11
PT85686B (en) 1990-05-31
HU199481B (en) 1990-02-28
CN87106838A (en) 1988-05-11
FI86428B (en) 1992-05-15
ZA876636B (en) 1988-07-27
NO169125B (en) 1992-02-03
JPH07138262A (en) 1995-05-30
MX8302A (en) 1993-12-01
DZ1124A1 (en) 2004-09-13
SK660487A3 (en) 1998-05-06
FI873940A (en) 1988-03-13
DK477287A (en) 1988-03-13
CZ281195B6 (en) 1996-07-17
IE872444L (en) 1988-03-12
JPH07138256A (en) 1995-05-30
IL83814A (en) 1991-09-16
JPH0826030B2 (en) 1996-03-13
CZ660487A3 (en) 1996-04-17
NO169125C (en) 1992-05-13

Similar Documents

Publication Publication Date Title
CN1028226C (en) 4-Oxoquinoline-3-carboxylic acid derivatives, their preparation and their use
CN1021052C (en) 8-alkoxyquinolonecar boxylic acid and salts thereof excellent in selective toxicity and process of preparing same
CN1022036C (en) Process for preparing cephalosporim compounds
CN1289500C (en) Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
CN1036193C (en) Preparation of a sprio compound
CN1068115A (en) 7-iso-dihydro-indole-group-quinolone and-1,4 dihydros-1,8 naphthyridine-4-keto carboxylic acid derivatives
CN1520412A (en) New derivatives of oxazolidinones as antibacterial agents
CN1087634A (en) 7-isoindolinyl-Carbostyril derivative and 7-isoindolinyl-naphthyridinone derivatives
CN1017800B (en) Tricyclic compounds
CN1103534A (en) Compound with antipsychotic effect
CN87100354A (en) The derivative of 7-(azabicycloalkyl)-quinolone carboxylic acid and 7-(azabicycloalkyl)-naphthyridonecarboxylic
CN1054980A (en) Optically active 8-BAY 128039 carboxylic acid derivative, their preparation method and their intermediate
CN1045972A (en) 5-replaces-1,4-dihydro-4-oxo-naphthyridine-3-carboxylic acid (ester) antimicrobial drug
CN1069640C (en) Adhesion receptor antagonists
CN1179962C (en) Azaindolizinone derivatives and cerebral function improvers containing the same as the active ingredient
CN87107226A (en) Lactam derivatives and preparation thereof
CN86102350A (en) Process for the preparation of novel * compounds
CN1277823C (en) New benzothiazine and benzothiadiazine compounds,its preparation process and pharmaceutical composition containing said compounds
CN1026785C (en) Process for preparing clausenamide and neoclausenamide, and of their derivatives
CN1274678C (en) New benzothiazine and benzothiadiazine compounds,its preparation process and pharmaceutical composition containing said compounds
CN1902202A (en) Diaza-spiropiperidine derivatives
CN1052003C (en) Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides
CN1059339A (en) New quinoline carboxylic acid derivative, the antiseptic-germicide that contains them and their method for making
CN1028531C (en) 1-oxa-2-oxo-8-azaspiro [4,5] decane derivatives, pharmaceutical compositions containing them and process for preparing same
CN1028102C (en) Process for spiro compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C13 Decision
GR02 Examined patent application
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term